المؤلفون: L. T. Akhmedzhanova, E. V. Mandra, Л. Т. Ахмеджанова, Е. В. Мандра

المصدر: Meditsinskiy sovet = Medical Council; № 23 (2022); 86-92 ; Медицинский Совет; № 23 (2022); 86-92 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: альфа-липоевая кислота, chronic painful diabetic polyneuropathy, acute painful diabetic polyneuropathy, neuropathic pain, alpha-lipoic acid, хроническая болевая диабетическая полиневропатия, острая болевая диабетическая полиневропатия, невропатическая боль

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7295/6517; Zheng Y., Ley S.H., Hu F.B. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98. https://doi.org/10.1038/nrendo.2017.151.; Pop-Busui R., Boulton A.J., Feldman E.L., Bril V., Freeman R., Malik R.A. et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. https://doi.org/10.2337/dc16-2042.; Andersen S.T., Witte D.R., Dalsgaard E.M., Andersen H., Nawroth P., Fleming T. et al. Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. Diabetes Care. 2018;41(5):1068–1075. https://doi.org/10.2337/dc17-2062.; Prabodha L.B.L., Sirisena N.D., Dissanayake V.H.W. Susceptible and Prognostic Genetic Factors Associated with Diabetic Peripheral Neuropathy: A Comprehensive Literature Review. Int J Endocrinol. 2018:8641942. https://doi.org/10.1155/2018/8641942.; Dyck P.J., Albers J.W., Andersen H., Arezzo J.C., Biessels G.J., Bril V. et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. https://doi.org/10.1002/dmrr.1226.; Boulton A.J.M., Armstrong D.G., Hardman M.J., Malone M., Embil J.M., Attinger C.E. et al. Diagnosis and Management of Diabetic Foot Infections. Arlington (VA): American Diabetes Association; 2020. https://doi.org/10.2337/db2020-01.; Selvarajah D., Kar D., Khunti K., Davies M.J., Scott A.R., Walker J., Tesfaye S. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol. 2019;7(12):938–948. https://doi.org/10.1016/S2213-8587(19)30081-6.; Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–2224. https://doi.org/10.2337/dc11-1108.; Rastogi A., Jude E.B. Novel treatment modalities for painful diabetic neuropathy. Diabetes Metab Syndr. 2021;15(1):287–293. https://doi.org/10.1016/j.dsx.2021.01.004.; Hosseini A., Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. Oxid Med Cell Longev. 2013:168039. https://doi.org/10.1155/2013/168039.; Feldman E.L., Nave K.A., Jensen T.S., Bennett D.L.H. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron. 2017;93(6):1296–1313. https://doi.org/10.1016/j.neuron.2017.02.005.; Callaghan B.C., Gallagher G., Fridman V., Feldman E.L. Diabetic neuropathy: what does the future hold? Diabetologia. 2020;63(5):891–897. https://doi.org/10.1007/s00125-020-05085-9.; Rosenberger D.C., Blechschmidt V., Timmerman H., Wolff A., Treede R.D. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm (Vienna). 2020;127(4):589–624. https://doi.org/10.1007/s00702-020-02145-7.; Hébert H.L., Veluchamy A., Torrance N., Smith B.H. Risk factors for neuropathic pain in diabetes mellitus. Pain. 2017;158(4):560–568. https://doi.org/10.1097/j.pain.0000000000000785.; Ziegler D., Landgraf R., Lobmann R., Reiners K., Rett K., Schnell O., Strom A. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Res Clin Pract. 2018;139:147–154. https://doi.org/10.1016/j.diabres.2018.02.043.; Themistocleous A.C., Ramirez J.D., Shillo P.R., Lees J.G., Selvarajah D., Orengo C. et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016;157(5):1132–1145. https://doi.org/10.1097/j.pain.0000000000000491.; Raputova J., Srotova I., Vlckova E., Sommer C., Üçeyler N., Birklein F. et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain. 2017;158(12):2340–2353. https://doi.org/10.1097/j.pain.0000000000001034.; Calvo M., Dawes J.M., Bennett D.L. The role of the immune system in the generation of neuropathic pain. Lancet Neurol. 2012;11(7):629–642. https://doi.org/10.1016/S1474-4422(12)70134-5.; Sloan G., Selvarajah D., Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021;17(7):400–420. https://doi.org/10.1038/s41574-021-00496-z.; Tesfaye S., Selvarajah D., Gandhi R., Greig M., Shillo P., Fang F., Wilkinson I.D. Diabetic peripheral neuropathy may not be as its name suggests: evidence from magnetic resonance imaging. Pain. 2016;157(Suppl. 1):S72–S80. https://doi.org/10.1097/j.pain.0000000000000465.; Watanabe K., Hirano S., Kojima K., Nagashima K., Mukai H., Sato T. et al. Altered cerebral blood flow in the anterior cingulate cortex is associated with neuropathic pain. J Neurol Neurosurg Psychiatry. 2018;89(10):1082–1087. https://doi.org/10.1136/jnnp-2017-316601.; Selvarajah D., Heiberg-Gibbons F., Wilkinson I.D., Gandhi R., Tesfaye S. A magnetic resonance imaging volumetry study of regional brain atrophy in diabetic peripheral neuropathy. Diabetes. 2018;67(Suppl. 1):550-P. https://doi.org/10.2337/db18-550-P.; Divisova S., Vlckova E., Hnojcikova M., Skorna M., Nemec M., Dubovy P. et al. Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst. 2012;17(3):341–350. https://doi.org/10.1111/j.1529-8027.2012.00420.x.; Зиновьева О.Е., Ахмеджанова Л.Т., Остроумова Т.М., Солоха О.А., Янакаева Т.А. Ранняя диагностика вегетативной невропатии в амбулаторной практике. Нервные болезни. 2020;(4):69–74. https://doi.org/10.24412/2226-0757-2020-12248.; Gibbons C.H., Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain. 2015;138(Pt 1):43–52. https://doi.org/10.1093/brain/awu307.; Gibbons C.H. Treatment induced neuropathy of diabetes. Auton Neurosci. 2020;226:102668. https://doi.org/10.1016/j.autneu.2020.102668.; Максимова Н., Мошенина С. Диабетическая нейропатия, индуцированная лечением (синдром Элленберга). Врач. 2018;(9):53–57. https://doi.org/10.29296/25877305-2018-09-12.; Bellelli A., Santi D., Simoni M., Greco C. Diabetic Neuropathic Cachexia: A Clinical Case and Review of Literature. Life (Basel). 2022;12(5):680. https://doi.org/10.3390/life12050680.; Мозолевский Ю.В. Заболевания периферической нервной системы. М.: МЕДпресс-информ; 2019. 432 с.; Gibbons C.H. Treatment-Induced Neuropathy of Diabetes. Curr Diab Rep. 2017;17(12):127. https://doi.org/10.1007/s11892-017-0960-6.; Feldman E.L., Callaghan B.C., Pop-Busui R., Zochodne D.W., Wright D.E., Bennett D.L. et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. https://doi.org/10.1038/s41572-019-0092-1.; Weisman A., Bril V., Ngo M., Lovblom L.E., Halpern E.M., Orszag A., Perkins B.A. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS ONE. 2013;8(3):e58783. https://doi.org/10.1371/journal.pone.0058783.; Andersson C., Guttorp P., Särkkä A. Discovering early diabetic neuropathy from epidermal nerve fiber patterns. Stat Med. 2016;35(24):4427–4442. https://doi.org/10.1002/sim.7009.; Аветисов С.Э., Черненкова Н.А., Сурнина З.В., Ахмеджанова Л.Т., Фокина А.С., Строков И.А. Возможности ранней диагностики диабетической полинейропатии на основе исследования нервных волокон роговицы. Вестник офтальмологии. 2020;136(5):155–162. https://doi.org/10.17116/oftalma2020136052155.; England J.D., Gronseth G.S., Franklin G., Carter G.T., Kinsella L.J., Cohen J.A. et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):185–192. https://doi.org/10.1212/01.wnl.0000336370.51010.a1.; Sharma J.K., Rohatgi A., Sharma D. Diabetic autonomic neuropathy: a clinical update. J R Coll Physicians Edinb. 2020;50(3):269–273. https://doi.org/10.4997/JRCPE.2020.310.; Salehi B., Berkay Yılmaz Y., Antika G., Boyunegmez Tumer T., Fawzi Mahomoodally M., Lobine D. et al. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019;9(8):356. https://doi.org/10.3390/biom9080356.; Islam M.T. Antioxidant activities of dithiol alpha-lipoic acid. Bangladesh J Med Sci. 2009;8(3):46–51. https://doi.org/10.3329/bjms.v8i3.398.; Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995;38(12):1425–1433. https://doi.org/10.1007/BF00400603.; Ziegler D., Hanefeld M., Ruhnau K.J., Hasche H., Lobisch M., Schütte K. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22(8):1296–1301. https://doi.org/10.2337/diacare.22.8.1296.; Ametov A.S., Barinov A., Dyck P.J., Hermann R., Kozlova N., Litchy W.J. et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26(3):770–776. https://doi.org/10.2337/diacare.26.3.770.; Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004;21(2):114–121. https://doi.org/10.1111/j.1464-5491.2004.01109.x.; El-Nahas M.R., Elkannishy G., Abdelhafez H., Elkhamisy E.T., El-Sehrawy A.A. Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1531–1534. https://doi.org/10.2174/1871530320666200506081407.; Patel K., Horak H., Tiryaki E. Diabetic neuropathies. Muscle Nerve. 2021;63(1):22–30. https://doi.org/10.1002/mus.27014.; Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R.H. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. https://doi.org/10.1016/S1474-4422(14)70251-0.; Dworkin R.H., Jensen M.P., Gammaitoni A.R., Olaleye D.O., Galer B.S. Symptom profiles differ in patients with neuropathic versus non-neuropathic pain. J Pain. 2007;8(2):118–126. https://doi.org/10.1016/j.jpain.2006.06.005.; Tesfaye S., Wilhelm S., Lledo A., Schacht A., Tölle T., Bouhassira D. et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain. 2013;154(12):2616–2625. https://doi.org/10.1016/j.pain.2013.05.043.; Zilliox L., Russell J.W. Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine. Diabetes Metab Syndr Obes. 2010;3:7–17. https://doi.org/10.2147/DMSOTT.S4719.; Marshall A., Alam U., Themistocleous A., Calcutt N., Marshall A. Novel and Emerging Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy. Clin Ther. 2021;43(9):1441–1456. https://doi.org/10.1016/j.clinthera.2021.03.020.; https://www.med-sovet.pro/jour/article/view/7295

الاتاحة: https://www.med-sovet.pro/jour/article/view/7295
https://doi.org/10.21518/2079-701X-2022-16-23-86-92

المؤلفون: E. V. Eliseeva, E. S. Maneeva, V. V. Gribova, D. B. Okun, D. V. Savitskaya

المصدر: Качественная клиническая практика, Vol 0, Iss 1, Pp 85-93 (2021)

مصطلحات موضوعية: льготное лекарственное обеспечение, программа обеспечения отдельных категорий граждан необходимыми лекарственными препаратами, тиоктовая (альфа-липоевая) кислота, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441

وصف الملف: electronic resource

Relation: https://www.clinvest.ru/jour/article/view/566; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473

URL الوصول: https://doaj.org/article/114e297054384075b1a44fb33f9b676d

المؤلفون: O. Zinovyeva E., P. Egorov D., V. Novikov N., I. Lovchev M., О. Зиновьева Е., П. Егоров Д., В. Новиков Н., И. Ловчев М.

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2022); 95-99 ; Медицинский Совет; № 2 (2022); 95-99 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: diabetes mellitus, diabetic polyneuropathy, pathogenetic treatment, alpha-lipoic acid, neurotropic B vitamins, сахарный диабет, диабетическая полиневропатия, патогенетическое лечение, альфа-липоевая кислота, нейротропные витамины группы В

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6743/6085; Дедов И.И., Шестакова М.В., Викулова О.К., Исаков М.А., Железнякова А.В. Атлас регистра сахарного диабета Российской Федерации. Статус 2018 г. Сахарный диабет. 2019;22(2S):4–61. https://doi.org/10.14341/dm12208.; Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(Suppl 1):S15–S33. https://doi.org/10.2337/dc21-S002.; Pop-Busui R., Boulton A.J.M., Feldman E.L., Bril V., Freeman R., Malik R.A. et al. Diabetic Neuropathy: a Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. https://doi.org/10.2337/dc16-2042.; Paisley A.N., Abbott C.A., van Schie C.H.M., Boulton A.J.M. A comparison of the Neuropen against standard quantitative sensory-threshold measures for assessing peripheral nerve function. Diabet Med. 2002;19(5):400–405. https://doi.org/10.1046/j.1464-5491.2002.00706.x.; Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev. 2011;7(3):208–220. https://doi.org/10.2174/157339911795843113.; Al-Attas O.S., Al-Daghri N.M., Alfadda A.A., Abd-Alrahman S.H., Sabico S. Blood thiamine and its phosphate esters as measured by high-performance liquid chromatography: levels and associations in diabetes mellitus patients with varying degrees of microalbuminuria. J Endocrinol Invest. 2012;35(11):951–956. https://doi.org/10.3275/8126.; Whitfield K.C., Bourassa M.W., Adamolekun B., Bergeron G., Bettendorff L., Brown K.H. et al. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018;1430(1):3–43. https://doi.org/10.1111/nyas.13919.; Ziegler D., Papanas N., Zhivov A., Allgeier S., Winter K., Ziegler I. et al. Early detection of nerve fiber loss by corneal confocal microscopy and skin biopsy in recently diagnosed type 2 diabetes. Diabetes. 2014;63(7):2454–2463. https://doi.org/10.2337/db13-1819.; Rochette L., Ghibu S., Muresan A., Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015;93(12):1021–1027. https://doi.org/10.1139/cjpp-2014-0353.; Papanas N., Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721–2731. https://doi.org/10.1517/14656566.2014.972935.; Бреговский В.Б., Храмилин В.Н., Демидова И.Ю., Строков И.А., Гурьева И.В. Диабетическая дистальная полинейропатия: обзор современных рекомендаций. Анналы клинической и экспериментальной неврологии. 2015;9(1):60–68. Режим доступа: https://cyberleninka.ru/article/n/diabeticheskaya-distalnaya-polineyropatiya-obzor-sovremennyhrekomendatsiy/pdf.; Строков И.А., Фокина А.С., Головачева В.А. Следует ли лечить диабетическую полиневропатию альфа-липоевой кислотой? Эффективная фармакотерапия. 2013;32(3):40–46. Режим доступа: https://umedp.ru/articles/sleduet_li_lechit_diabeticheskuyu_polinevropatiyu_alfalipoevoy_kislotoy.html.; Liu L., Huang X., Wang B., Song Y., Lin T., Zhou Z. et al. Vitamin B12 and risk of diabetes: new insight from cross-sectional and longitudinal analyses of the China Stroke Primary Prevention Trial (CSPPT). BMJ Оpen Diabetes Res Care. 2020;8(1):e001423. https://doi.org/10.1136/bmjdrc-2020-001423.; Yang W., Cai X., Wu H., Ji L. Associations between metformin use and vitamin B 12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019;11(9):729–743. https://doi.org/10.1111/1753-0407.12900.; Jayabalan B., Low L.L. Vitamin B supplementation for diabetic peripheral neuropathy. Singapore Med J. 2016;57(2):55–59. https://doi.org/10.11622/smedj.2016027.; Mascolo E., Vernì F. Vitamin B6 and Diabetes: Relationship and Molecular Mechanisms. Int J Mol Sci. 2020;21(10):3669. https://doi.org/10.3390/ijms21103669.; Valdés-Ramos R., Guadarrama-López A.L., Martínez-Carrillo B.E., BenítezArciniega A.D. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets. 2015;15(1):54–63. https://doi.org/10.2174/1871530314666141111103217.; Громова О.А., Стаховская Л.В., Торшин И.Ю., Томилова И.К. Прием метформина провоцирует нарушения гомеостаза витамина В12. Consilium Medicum. 2017;19(4):58–64. Режим доступа: https://cyberleninka.ru/article/n/priem-metformina-provotsiruet-narusheniya-gomeostazavitamina-v12/pdf.; https://www.med-sovet.pro/jour/article/view/6743

الاتاحة: https://www.med-sovet.pro/jour/article/view/6743
https://doi.org/10.21518/2079-701X-2022-16-2-95-99

المؤلفون: O. Zinovyeva E., T. Ostroumova M., M. Koniashova V., N. Gorbachev A., О. Зиновьева Е., Т. Остроумова М., М. Коняшова В., Н. Горбачев А.

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 5 (2021); 116-122 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 5 (2021); 116-122 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-5

مصطلحات موضوعية: prediabetes, diabetic neuropathy, peripheral nervous system, alpha-lipoic acid, предиабет, диабетическая невропатия, периферическая нервная система, альфа-липоевая кислота

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1675/1320; Шестакова МВ, Викулова ОК, Железнякова АВ и др. Эпидемиология сахарного диабета в Российской Федерации: что изменилось за последнее десятилетие? Терапевтический архив. 2019;91(10):4-13. doi:10.26442/00403660.2019.10.000364; Дедов ИИ, Шестакова МВ, Майоров АЮ и др. Сахарный диабет 2 типа у взрослых. Сахарный диабет. 2020;23(2S):4-102. doi:10.14341/DM12507; Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323. doi:10.1093/eurheartj/ehz486; International Diabetes Federation. IDF Diabetes Atlas, 9 th ed. Brussels, Belgium: 2019. Available from: https://www.diabetesatlas.org; Pfannkuche A, Alhajjar A, Ming A, et al. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative «diabetes and nerves». Endocr Metab Sci. 2020 Jul;1(1-2):100053. doi:10.1016/j.endmts.2020.100053; Stino AM, Smith AG. Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017 Sep;8(5):646-55. doi:10.1111/jdi.12650; Kirthi V, Perumbalath A, Brown E, et al. Prevalence of peripheral neuropathy in pre-diabetes: a systematic review. BMJ Open Diabetes Res Care. 2021 May;9(1):e002040. doi:10.1136/bmjdrc-2020-002040; American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021 Jan;44(Suppl. 1):S15-S33. doi:10.2337/dc21-S002; Barrell K, Smith AG. Peripheral Neuropathy. Med Clin North Am. 2019 Mar;103(2):383-97. doi:10.1016/j.mcna.2018.10.006; Ziegler D, Rathmann W, Dickhaus T, et al. Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care. 2008 Mar;31(3):464-9. doi:10.2337/dc07-1796; Kazamel M, Stino AM, Smith AG. Metabolic syndrome and peripheral neuropathy. Muscle Nerve. 2021 Mar;63(3):285-93. doi:10.1002/mus.27086; Ziegler D, Rathmann W, Dickhaus T, et al. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med. 2009 Mar;10(2):393-400. doi:10.1111/j.1526-4637.2008.00555.x; Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care. 2015 May;38(5):793-800. doi:10.2337/dc14-2585; Spallone V. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J. 2019 Feb;43(1):3-30. doi:10.4093/dmj.2018.0259; Ziegler D, Voss A, Rathmann W, et al. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia. 2015 May;58(5):1118-28. doi:10.1007/s00125-015-3534-7; Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:136-54. doi:10.2337/dc16-2042; Дедов ИИ, Шестакова МВ, Майоров АЮ, редакторы. Алгоритмы специализированной медицинской помощи больным сахарным диабетом: Клинические рекомендации. 9-й выпуск. Сахарный диабет. 2019;22(1S1):1-144. doi:10.14341/DM221S1; American Diabetes Association. Microvascular complications and foot care: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021 Jan;44(Suppl. 1):S151-S167. doi:10.2337/dc21-S011; Papanas N, Ziegler D. Prediabetic neuropathy: does it exist? Curr Diab Rep. 2012 Aug;12(4):376-83. doi:10.1007/s11892-012-0278-3; Zeng J, Xu Y, Shi Y, Jiang C. Inflammation role in sensory neuropathy in Chinese patients with diabetes/prediabetes. Clin Neurol Neurosurg. 2018 Mar;166:136-40. doi:10.1016/j.clineuro.2018.01.031; Van der Velde JHPM, Koster A, Strotmeyer ES, et al. Cardiometabolic risk factors as determinants of peripheral nerve function: the Maastricht Study. Diabetologia. 2020 Aug;63(8):1648-58. doi:10.1007/s00125-020-05194-5; Kopf S, Groener JB, Kender Z, et al. Deep phenotyping neuropathy: An underestimated complication in patients with pre-diabetes and type 2 diabetes associated with albuminuria. Diabetes Res Clin Pract. 2018 Dec;146:191-201. doi:10.1016/j.diabres.2018.10.020; Thaisetthawatkul P, Fernandes Filho JA, Herrmann DN. Contribution of QSART to the diagnosis of small fiber neuropathy. Muscle Nerve. 2013 Dec;48(6):883-8. doi:10.1002/mus.23891; McArthur JC. Painful small fiber neuropathies. Continuum (Minneap Minn). 2012 Feb;18(1):106-25. doi:10.1212/01.CON.0000411570.79827.25; Divisova S, Vlckova E, Hnojcikova M, et al. Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst. 2012 Sep;17(3):341-50. doi:10.1111/j.1529-8027.2012.00420.x; Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care. 2014 Sep;37(9):2643-6. doi:10.2337/dc14-0279; DelMonte DW, Kim T. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011 Mar;37(3):588-98. doi:10.1016/j.jcrs.2010.12.037; Jende JME, Kender Z, Mooshage C, et al. Diffusion Tensor Imaging of the Sciatic Nerve as a Surrogate Marker for Nerve Functionality of the Upper and Lower Limb in Patients With Diabetes and Prediabetes. Front Neurosci. 2021 Mar;15:642589. doi:10.3389/fnins.2021.642589; Suo M, Wang P, Zhang M. Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice. J Neurophysiol. 2016 Aug;116(2):448-55. doi:10.1152/jn.00229.2016; Hinder LM, O'Brien PD, Hayes JM, et al. Dietary reversal of neuropathy in a murine model of prediabetes and metabolic syndrome. Dis Model Mech. 2017 Jun;10(6):717-25. doi:10.1242/dmm.028530; Roncero-Ramos I, Alcala-Diaz JF, Rangel-Zuniga OA, et al. Prediabetes diagnosis criteria, type 2 diabetes risk and dietary modulation: The CORDIOPREV study. Clin Nutr. 2020 Feb;39(2):492-500. doi:10.1016/j.clnu.2019.02.027; Hemmingsen B, Gimenez-Perez G, Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 Dec 4;12(12):CD003054. doi:10.1002/14651858.CD003054.pub4; Gong Q, Zhang P, Wang J, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019 Jun;7(6):452-61. doi:10.1016/S2213-8587(19)30093-2; Nathan DM, Barrett-Connor E, Crandall JP, et al. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-75. doi:10.1016/S2213-8587(15)00291-0; Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006 Jun;29(6):1294-9. doi:10.2337/dc06-0224; Groover AL, Ryals JM, Guilford BL, et al. Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain. 2013 Dec;154(12):2658-67. doi:10.1016/j.pain.2013.07.052; Carnethon MR, Prineas RJ, Temprosa M, et al. The association among autonomic nervous system function, incident diabetes, and intervention arm in the Diabetes Prevention Program. Diabetes Care. 2006 Apr;29(4):914-9. doi:10.2337/diacare.29.04.06.dc05-1729; Madsen KS, Chi Y, Metzendorf MI, et al. Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2019 Dec;12(12):CD008558. doi:10.1002/14651858.CD008558.pub2; Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018 Dec;12(12):CD005061. doi:10.1002/14651858.CD005061.pub3; Hemmingsen B, Sonne DP, Metzendorf MI, Richter B. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 May;5(5):CD012204. doi:10.1002/14651858.CD012204.pub2; Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind. World J Diabetes. 2021 Jul;12(7):916-31. doi:10.4239/wjd.v12.i7.916; Inzucchi SE, Docherty KF, Kњber L, et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care. 2021 Feb;44(2):586-94. doi:10.2337/dc20-1675; Gabriel R, Boukichou Abdelkader N, Acosta T, et al. Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data. PLoS One. 2020 Apr;15(4):e0231196. doi:10.1371/journal.pone.0231196; Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019 Jun;5(1):41. doi:10.1038/s41572-019-0092-1; Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014 Feb;80:21-35. doi:10.1016/j.phrs.2013.12.005; Rahimlou M, Asadi M, Banaei Jahromi N, Mansoori A. Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: A Systematic Review and meta-analysis. Clin Nutr ESPEN. 2019 Aug;32:16-28. doi:10.1016/j.clnesp.2019.03.015; Han T, Bai J, Liu W, Hu Y. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012 Oct;167(4):465-71. doi:10.1530/EJE-12-0555; Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 year in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503; Gosselin LE, Chrapowitzky L, Rideout TC. Metabolic effects of α-lipoic acid supplementation in pre-diabetics: a randomized, placebo-controlled pilot study. Food Funct. 2019 Sep;10(9):5732-8. doi:10.1039/c9fo00390h; Haghighatdoost F, Hariri M. Does alpha-lipoic acid affect lipid profile? A meta-analysis and systematic review on randomized controlled trials. Eur J Pharmacol. 2019 Mar;847:1-10. doi:10.1016/j.ejphar.2019.01.001; https://nnp.ima-press.net/nnp/article/view/1675

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1675
https://doi.org/10.14412/2074-2711-2021-5-116-122

المؤلفون: I. Strokov A., V. Oganov V., И. Строков А., В. Оганов В.

المساهمون: This article has been supported by Kanonfarma prodakshn, Статья спонсируется компанией ЗАО «Канонфарма продакшн»

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 3 (2021); 99-106 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 3 (2021); 99-106 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-3

مصطلحات موضوعية: diabetes mellitus, diabetic polyneuropathy, evaluation, pathogenetic therapy, alpha-lipoic acid, symptom-modifying treatment, disease-modifying treatment, сахарный диабет, диабетическая полиневропатия, диагностика, патогенетическая терапия, альфа-липоевая кислота, симптом-модифицирующая терапия, болезнь-модифицирующая терапия

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1584/1262; Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA. 2017 Jun 27;317(24):2515-23. doi:10.1001/jama.2017.7596; International Diabetes Federation Atlas. 8th ed. 2017. Available from: https://diabetesatlas.org/upload/resources/previous/files/8/IDF_DA_8e-EN-final.pdf; Котов СВ, Калинин АП, Рудакова ИГ. Диабетическая нейропатия. Москва: МИА; 2011. 438 с.; Tesfaye S, Boulton AJM, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010 Oct;33(10):2285-93. doi:10.2337/dc10-1303; Babizhayev MA, Nosikov VV, Strokov IA, et al. The role of oxidative stress in diabetic neuropathy: generation of free radical species in the glycation reaction and gene polymorphisms encoding antioxidant enzymes to genetic susceptibility to diabetic neuropathy in population of type I diabetic patients. Cell Biochem Biophys. 2015 Apr;71(3):1425-43. doi:10.1007/s12013-014-0365-y; Strokov IA, Bursa TR, Drepa OI, et al. Predisposing genetic factors for diabetic polyneuropathy in patients with type 1 diabetes: a population-based case-control study. Acta Diabetol. 2003 Dec;40 Suppl 2:S375-9. doi:10.1007/s00592-003-0123-x; Albers JW, Pop-Busui R. Diabetic neuropathy: mechanisms, emerging treatments, and subtypes. Curr Neurol Neurosci Rep. 2014 Aug;14(8):473. doi:10.1007/s11910-014-0473-5; Строков ИА, Мельниченко ГА, Альбекова ЖС и др. Распространенность и факторы риска развития диабетической полиневропатии у стационарных больных сахарным диабетом 1-го типа. Нервно-мышечные болезни. 2012;(1):25-31. doi:10.17650/2222-8721-2012-0-1-25-31; The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995 Apr 15;122(8):561-8. doi:10.7326/0003-4819-122-8-199504150-00001; Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012 Jun 13;6(6):CD007543. doi:10.1002/14651858.CD007543.pub2; Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes. 2005 Jun;54(6):1615-25. doi:10.2337/diabetes.54.6.1615; Edwards JL, Vincent AM, Cheng HT, et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther. 2008 Oct;120(1):1-34. doi:10.1016/j.pharmthera.2008.05.005. Epub 2008 Jun 13.; Зотова ЕВ, Савостьянов КВ, Чистяков ДА и др. Поиск ассоциации полиморфных маркеров генов, кодирующих ферменты антиоксидантной защиты с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2004;(2):244-9.; Зотова ЕВ, Чистяков ДА, Савостьянов КВ и др. Изучение ассоциации полиморфных маркеров Ala(-9) Val гена SOD2 и Arg213Gly гена SOD3 с диабетической полинейропатией у больных сахарным диабетом типа 1. Молекулярная биология. 2003;(3):345-8.; Malic RA, Tesfaye S, Thompson SD, et al. Microangiopathy in human diabetic neuropathy: relationship between capilliary abnormalities and severity of neuropathy. Diabetologia. 1993 May;36(5):454-9. doi:10.1007/BF00402283; Giannini C, Dyck PJ. Ultrastructural morphometric features in human sural nerve microvessels. J Neuropathol Exp Neurol. 1993 Jul;52(4):361-9. doi:10.1097/00005072-199307000-00003; Caneron NE, Cotter MA. Pro-inflammatory mechanisms in diabetic neuropathy: focus on the nuclear factor kappa B pathway. Curr Drug Targets. 2008 Jan;9(1):60-7. doi:10.2174/138945008783431718; Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin Neurol Neurosurg. 2006 Jul;108(5):477-81. doi:10.1016/j.clineuro.2005.08.003. Epub 2005 Sep 16.; Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015 Feb;14(2):162-73. doi:10.1016/S1474-4422(14)70251-0. Epub 2015 Jan 7.; Vincent AM, Callaghan BC, Smith AL, et al. Fiabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011 Sep 13;7(10):573-83. doi:10.1038/nrneurol.2011.137; Boulton AJ, Kempler P, Ametov A, et al. Whither pathogenetic treatments for diabetic polyneuropathy? Diabetes Metab Res Rev. 2013 Jul;29(5):327-33. doi:10.1002/dmrr.2397; Строков ИА, Манухина ЕБ, Бахтина ЛЮ и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полинейропатией: эффект антиоксидантной терапии. Бюллетень экспериментальной биологии и медицины. 2000;130(10):437-41.; Borcea V, Nourooz-Zadeh J, Wolff SP, et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med. 1999 Jun;26(11-12):1495-500. doi:10.1016/s0891-5849(99)00011-8; Haak ES, Usadel KH, Kohleisen M, et al. The effect of α-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. Microvasc Res. 1999 Jul;58(1):28-34. doi:10.1006/mvre.1999.2151; Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi:10.1007/BF00400603; Строков ИА, Козлова НА, Мозолевский ЮВ. Эффективность внутривенного введения трометамоловой соли тиоктовой (α-липоевой) кислоты при диабетической невропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 1999;(6):18-22.; Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with antioxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114-21. doi:10.1111/j.1464-5491.2004.01109.x; Ruhnau KJ, Meissner HP, Finn JR, et al. Effect of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diab Med. 1999 Dec;16(12):1040-3. doi:10.1046/j.1464-5491.1999.00190.x; Ziegler D, Ametov A, Barinov A, et al. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care. 2006 Nov;29(11):2365-70. doi:10.2337/dc06-1216; Строков ИА, Фокина АС, Головачева ВА, Кочетов АГ. Эффективность тиолепты при диабетической полиневропатии (по данным исследования ЭТИКА). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(5):36-40.; Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: A position statement by the American Diabetes Association. Diabetic Care. 2017 Jan;40(1):136-54. doi:10.2337/dc16-2042; Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503. Epub 2011 Jul 20.; Strokov IA, Novosadova MV, Lavrova IN, et al. The prolonged clinical effect of tioctic acid in symptomatic distal diabetic polyneuropathy. Abstr. of the 14th Annual Scientific Meeting of the DFSG and NEURODIAB, Regensburg, Germany, September 2–5 2004; 195 p.; Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with antioxidant thioctic acid (alpha-lipoic acid): a two-year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Free Rad Res. 1999 Sep;31(3):171-9. doi:10.1080/10715769900300721; https://nnp.ima-press.net/nnp/article/view/1584

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1584
https://doi.org/10.14412/2074-2711-2021-3-99-106

المؤلفون: N. Pizova V., Н. Пизова В.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2021); 134-146 ; Медицинский Совет; № 19 (2021); 134-146 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: metabolic and toxic polyneuropathies, clinic, risk factors, therapeutic approaches, alpha-lipoic acid, метаболические и токсические полинейропатии, клиника, факторы риска, терапевтические подходы, альфа-липоевая кислота

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/6542/5927; Kieseier B.C., Hartung H.P. Progress in Recognizing and Treating Polyneuropathy. Dtsch Arztebl Int. 2018;115(6):81–82. https://doi.org/10.3238/arztebl.2018.0081.; Grantz M., Huan M.C. Unusual peripheral neuropathies. Part I: extrinsic causes. Semin Neurol. 2010;30(4):387–395. https://doi.org/10.1055/s-0030-1267282.; Grantz M. Unusual peripheral neuropathies. Part II: intrinsic reactive causes. Semin Neurol. 2010;30(4):396–404. https://doi.org/10.1055/s-0030-1267283.; Grantz M. Unusual peripheral neuropathies. Part III: intrinsic inherited causes. Semin Neurol. 2010;30(4):405–415. https://doi.org/10.1055/s-0030-1267284.; Burns T.M., Mauermann M.L. The evaluation of polyneuropathies. Neurology. 2011;76(7 Suppl.):6–13. https://doi.org/10.1212/WNL.0b013e31820c3622.; England J.D., Gronseth G.S., Franklin G., Carter G.T., Kinsella L.J., Cohe J.A. et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidencebased review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):177–184. https://doi.org/10.1212/01.wnl.0000336345.70511.0f.; Hanewinckel R., van Oijen M., Ikram M.A., van Doorn P.A. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31(1):5–20. https://doi.org/10.1007/s10654-015-0094-6.; Bharucha N.E., Bharucha A.E., Bharucha E.P. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology. 1991;41(8):1315–1317. https://doi.org/10.1212/wnl.41.8.1315.; Savettieri G., Rocca W.A., Salemi G., Meneghini F., Grigoletto F., Morgante L. et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1993;43(6):1115–1120. https://doi.org/10.1212/wnl.43.6.1115.; Cruz M.E., Schoenberg B.S., Ruales J., Barberis P., Proano J., Bossano F. et al. Pilot study to detect neurologic disease in Ecuador among a population with a high prevalence of endemic goiter. Neuroepidemiology. 1985;4(2):108–116. https://doi.org/10.1159/000110221.; Osuntokun B.O., Adeuja A.O., Schoenberg B.S., Bademosi O., Nottidge V.A., Olumide A.O. et al. Neurological disorders in Nigerian Africans: a community-based study. Acta Neurol Scand. 1987;75(1):13–21. https://doi.org/10.1111/j.1600-0404.1987.tb07883.x.; Cruz Gutierrez-del-Olmo M., Schoenberg B.S., Portera-Sanchez A. Prevalence of neurological diseases in Madrid, Spain. Neuroepidemiology. 1989;8(1):43–47. https://doi.org/10.1159/000110164.; Longe A.C., Osuntokun B.O. Prevalence of neurological disorders in Udo, a rural community in southern Nigeria. Trop Geogr Med. 1989;41(1):36–40. Available at: https://pubmed.ncbi.nlm.nih.gov/2763344.; Al Rajeh S., Bademosi O., Ismail H., Awada A., Dawodu A., Al-Freihi H. et al. A community survey of neurological disorders in Saudi Arabia: the Thugbah study. Neuroepidemiology. 1993;12(3):164–178. https://doi.org/10.1159/000110316.; Kandil M.R., Darwish E.S., Khedr E.M., Sabry M.M., Abdulah M.A. A community-based epidemiological study of peripheral neuropathies in Assiut, Egypt. Neurol Res. 2012;34(10):960–966. https://doi.org/10.1179/1743132812Y.0000000099.; Kruja J., Beghi E., Zerbi D., Dobi D., Kuqo A., Zekja I. et al. High prevalence of major neurological disorders in two Albanian communities: results of a door-to-door survey. Neuroepidemiology. 2012;38(3):138–147. https://doi.org/10.1159/000336348.; Lor T.L., Boon K.Y., Cheo F.F., Lau S.C., Lee G.W., Ng B.H., Go K.J. The frequency of symptomatic sensory polyneuropathy in the elderly in an urban Malaysian community. Neurol Asia. 2009;14(2):109–113. Available at: https://neurology-asia.org/articles/20092_109.pdf.; Dewhurst F., Dewhurst M.J., Gray W.K., Aris E., Orega G., Howlett W. et al. The prevalence of neurological disorders in older people in Tanzania. Acta Neurol Scand. 2013;127(3):198–207. https://doi.org/10.1111/j.1600-0404.2012.01709.x.; Rothman K.J., Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005;95(1 Suppl.):S144-S150. https://doi.org/10.2105/AJPH.2004.059204.; McNeely M., Boyko E., Ahroni J., Stensel V.L., Reiber G.E., Smith D.G., Pecoraro R.F. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care. 1995;18(2):216–219. https://doi.org/10.2337/diacare.18.2.216.; Russell J.W., Zilliox L.A. Diabetic neuropathies. Continuum (Minneap Minn). 2014;20(5):1226–1240. https://doi.org/10.1212/01.CON.0000455884.29545.d2.; Boulton A.J., Knight G., Drury J., Ward J.D. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care. 1985;8(2):125–128. https://doi.org/10.2337/diacare.8.2.125.; Dyck P.J., Kratz K.M., Karnes J.L., Litchy W.J., Klein R., Pach J.M. et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43(4):817–824. https://doi.org/10.1212/wnl.43.4.817.; Franklin G.M., Kahn L.B., Baxter J., Marshall J.A., Hamman R.F. Sensory neuropathy in non-insulin-dependent diabetes mellitus. The San Luis Valley Diabetes Study. Amer J Epid. 1990;131(4):633–643. https://doi.org/10.1093/oxfordjournals.aje.a115547.; Maser R.E., Steenkiste A.R., Dorman J.S., Nielsen V., Bass E., Manjoo Q. et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes. 1989;38(11):1456–1461. https://doi.org/10.2337/diab.38.11.1456.; Partanen J., Niskanen L., Lehtinen J., Mervaala E., Siitonen O., Uusitupa M. Natural history of peripheral neuropathy in patients with non-insulindependent diabetes mellitus. N Engl J Med. 1995;333(2):89–94. https://doi.org/10.1056/NEJM199507133330203.; Singleton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001;24(8):1448–1453. https://doi.org/10.2337/diacare.24.8.1448.; Feldman E.L., Callaghan B.C., Pop-Busui R., Zochodne D.W., Wright D.E., Bennett D.L. et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):42. https://doi.org/10.1038/s41572-019-0097-9.; Divisova S., Vlckova E., Hnojcikova M., Skorna M., Nemec M., Dubovy P. et al. Prediabetes/early diabetes-associated neuropathy predominantly involves sensory small fibres. J Peripher Nerv Syst. 2012;17(3):341–350. https://doi.org/10.1111/j.1529-8027.2012.00420.x.; Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large communitybased diabetic population in the U.K. Diabetes Care. 2011;34(10):2220–2224. https://doi.org/10.2337/dc11-1108.; Malik R.A. Can diabetic neuropathy be prevented by angiotensinconverting enzyme inhibitors? Ann Med. 2000;32(1):1–5. https://doi.org/10.3109/07853890008995903.; Tesfaye S., Stevens L., Stephenson J., Fuller J.H., Plater M., IonescuTirgoviste C. et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia. 1996;39(11):1377–1384. https://doi.org/10.1007/s001250050586.; Ropper A.H., Samuels M.A. (eds.). Adams and Victor’s Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009. Available at: https://pdfdrive.com/adams-and-victors-principles-of-neurology-d175302779.html.; Pop-Busui R., Boulton A.J.M., Feldman E.L., Bril V., Freeman R., Malik R.A. et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. https://doi.org/10.2337/dc16-2042.; Sinnreich M., Taylor B.V., Dyck P.J. Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist. 2005;11(2):63–79. https://doi.org/10.1097/01.nrl.0000156314.24508.ed.; Пизова Н.В. Некоторые клинические проявления поражения нервной системы при сахарном диабете. Медицинский cовет. 2018;(9):104–111. https://doi.org/10.21518/2079-701X-2018-9-104-111.; Dyck P.J., Albers J.W., Andersen H., Arezzo J.C., Biessels G.-J., Bril V. et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27(7):620–628. https://doi.org/10.1002/dmrr.1226.; Weisman A., Bril V., Ngo M., Lovblom L.E., Halpern E.M., Orszag A., Perkins B.A. Identification and prediction of diabetic sensorimotor polyneuropathy using individual and simple combinations of nerve conduction study parameters. PLoS ONE. 2013;8(3):e58783. https://doi.org/10.1371/journal.pone.0058783.; Perkins B.A., Orszag A., Ngo M., Ng E., New P.V., Bril V. Prediction of incident diabetic neuropathy using the monofilament examination: a 4-year prospective study. Diabetes Care. 2010;33(7):1549–1554. https://doi.org/10.2337/dc09-1835.; Boulton A.J., Armstrong D.G., Albert S.F., Frykberg R.G., Hellman R., Kirkman M.S. et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care. 2008;31(8):1679–1685. https://doi.org/10.2337/dc08-9021.; Kanji J.N., Anglin R.E., Hunt D.L., Panju A. Does this patient with diabetes have large-fiber peripheral neuropathy? JAMA. 2010;303(15):1526–1532. https://doi.org/10.1001/jama.2010.428.; Bouhassira D., Attal N., Alchaar H., Boureau F., Brochet B., Bruxelle J. et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1):29–36. https://doi.org/10.1016/j.pain.2004.12.010.; Krishnan A.V., Kiernan M.C. Neurological complications of chronic kidney disease. Nat Rev Neurol. 2009;5(10):542–551. https://doi.org/10.1038/nrneurol.2009.138.; Rizzo M.A., Frediani F., Granata A., Ravasi B., Cusi D., Gallieni M. Neurological complications of hemodialysis: state of the art. J Nephrol. 2012;25(2):170–182. https://doi.org/10.5301/jn.5000087.; Krishnan A.V., Kiernan M.C. Uremic neuropathy: clinical features and new pathophysiological insights. Muscle and Nerve. 2007;35(3):273–290. https://doi.org/10.1002/mus.20713.; Krishnan A.V., Pussell B.A., Kiernan M.C. Neuromuscular disease in the dialysis patient: an update for the nephrologist. Semin Dial. 2009;22(3):267–278. https://doi.org/10.1111/j.1525-139X.2008.00555.x.; Arnold R., Krishnan A. Neuropathy and other neurological problems in chronic kidney disease. In: Arici M. (ed.). Management of chronic kidney disease. Berlin: Springer; 2014, pp. 343–352. https://doi.org/10.1007/978-3-642-54637-2.; Pop-Busui R., Roberts L., Pennathur S., Kretzler M., Brosius F.C., Feldman E.L. The management of diabetic neuropathy in CKD. Am J Kidney Dis. 2010;55(2):365–385. https://doi.org/10.1053/j.ajkd.2009.10.050.; Прилепская О.А., Кичерова О.А., Рейхерт Л.И. Клинические особенности уремической полинейропатии. Академический журнал Западной Сибири. 2016;12(4):66–68. Режим доступа: https://s2.siteapi.org/2272b53cc9c3a55/docs/jjiyn25tfbscokcc444ks8ssc8o0so.; Lakshman S.G., Ravikumar P., Kar G., Das D., Bhattacharjee K., Bhattacharjee P. A Comparative Study of Neurological Complications in Chronic Kidney Disease with Special Reference to its Stages and Haemodialysis Status. J Clin Diagn Res. 2016;10(12):OC01-OC04. https://doi.org/10.7860/JCDR/2016/22815.8947.; Babu M.M., Kiran M.R., Ravindra K., Srinivas V., Kandregula P., Vardhan R.V., Kumar N. Clinical manifestation and prevalence of peripheral neuropathy and nerve dysfunction in patients with chronic kidney disease. IJRMS. 2015;3(2):451–455. https://doi.org/10.5455/2320-6012.ijrms20150213.; Arnold R., Issar T., Krishnan A., Pussell B. Neurological complications in chronic kidney disease. JRSM Cardiovasc Dis. 2016;5. https://doi.org/10.1177/2048004016677687.; Arnold R., Pussell B.A., Howells J, Grinius V., Kiernan M.C., Lin C., Krishnan A.V. Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clin Neurophysiol. 2014;125(1):179–185. https://doi.org/10.1016/j.clinph.2013.06.022.; McIntosh C. Alcohol and the nervous system. J Neurol Neurosurg Psychiatry. 2004;75:iii16-iii21. https://doi.org/10.1136/jnnp.2004.045708.; Ravaglia S., Marchioni E., Costa A., Maurelli M., Moglia A. Erectile dysfunction as a sentinel symptom of cardiovascular autonomic neuropathy in heavy drinkers. J Peripher Nerv Syst. 2004;9(4):209–214. https://doi.org/10.1111/j.1085-9489.2004.09403.x.; Koike H., Iijima M., Sugiura M., Mori K., Hattori N., Ito H. et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol. 2003;54(1):19–29. https://doi.org/10.1002/ana.10550.; Julian T., Glascow N., Syeed R., Zis P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol. 2019;266(12):2907–2919. https://doi.org/10.1007/s00415-018-9123-1.; Mygland A.M. P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol. 2001;8(2):157–165. https://doi.org/10.1046/j.1468-1331.2001.00187.x.; Lin K.P., Kwan S.Y., Chen S.Y., Chen S.S., Yeung K.B., Chia L.G., Wu Z.A. Generalized neuropathy in Taiwan: an etiologic survey. Neuroepidemiology. 1993;12:257–261. https://doi.org/10.1159/000110326.; Verghese J., Bieri P.L., Gellido C., Schaumburg H.H., Herskovitz S. Peripheral neuropathy in young-old and old-old patients. Muscle & Nerve. 2001;24(11):1476–1481. https://doi.org/10.1002/mus.1171.; Азимова Ю.Э., Ищенко К.А., Рачин А.П. Диагностика и лечение неврологических осложнений алкоголизма: «Новое вино в старых бокалах». Поликлиника. 2016;(1):50–56. Режим доступа: https://www.poliklin.ru/imagearticle/2016_1/50.pdf.; Mathis S., Soulages A., Vallat J.M., Le Masson G. Epidemics and outbreaks of peripheral nervous system disorders: II. Toxic and nutritional causes. J Neurol. 2021;268(3):892–902. https://doi.org/10.1007/s00415-020-10216-8.; Koike H., Sobue G. Alcoholic neuropathy. Curr Opin Neurol. 2006;19(5): 481–486. https://doi.org/10.1097/01.wco.0000245371.89941.eb.; Zambelis T., Karandreas N., Tzavellas E., Kokotis P., Liappas J. Large and small fiber neuropathy in chronic alcohol-dependent subjects. J Peripher Nerv Syst. 2005;10(4):375–381. https://doi.org/10.1111/j.1085-9489.2005.00050.x.; Palliyath S., Schwartz B.D. Peripheral nerve functions improve in chronic alcoholic patients on abstinence. J Stud Alcohol. 1993;54:684–686. https://doi.org/10.15288/jsa.1993.54.684.; Monforte R., Estruch R., Valls-Solé J., Nicolás J., Villalta J., UrbanoMarquez A. Autonomic and peripheral neuropathies in patients with chronic alcoholism. A dose-related toxic effect of alcohol. Arch Neurol. 1995;52(1):45–51. https://doi.org/10.1001/archneur.1995.00540250049012.; Vittadini G., Buonocore M., Colli G., Terzi M., Fonte R., Biscaldi G. Alcoholic polyneuropathy: a clinical and epidemiological study. Alcohol Alcohol. 2001;36(5):393–400. https://doi.org/10.1093/alcalc/36.5.393.; Ammendola A., Gemini D., Iannaccone S., Argenzio F., Ciccone G., Ammendola E. et al. Gender and peripheral neuropathy in chronic alcoholism: a clinical-electroneurographic study. Alcohol and Alcoholism. 2000;35:368–371. https://doi.org/10.1093/alcalc/35.4.368.; Agelink M.W., Malessa R., Weisser U., Lemmer W., Zeit T., Majewski T., Klieser E. Alcoholism, peripheral neuropathy (PNP) and cardiovascular autonomic neuropathy (CAN). J Neurol Sci. 1998;161(2):135–142. https://doi.org/10.1016/s0022-510x(98)00266-4.; Ammendola A., Tata M.R., Aurilio C., Ciccone G., Gemini D., Ammendola E. et al. Peripheral neuropathy in chronic alcoholism: a retrospective crosssectional study in 76 subjects. Alcohol and Alcoholism. 2001;36(3): 271–275. https://doi.org/10.1093/alcalc/36.3.271.; Ng K., Lin C.S.-Y., Murray N.M. F., Burroughs A.K., Bostock H. Conduction and excitability properties of peripheral nerves in end-stage liver disease. Muscle & Nerve. 2007;35(6):730–738. https://doi.org/10.1002/mus.20765.; Estruch R., Nicolás J.M., Villegas E., Junqué A., Urbano-Márquez A. Relationship between ethanol-related diseases and nutritional status in chronically alcoholic men. Alcohol and Alcoholism. 1993;28(5):543–550. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8274178.; Michalak S., Michałowska-Wender G., Adamcewicz G., Wender M.B. Erythrocyte transketolase activity in patients with diabetic and alcoholic neuropathies. Folia Neuropathol. 2013;51(3):222–226. https://doi.org/10.5114/fn.2013.37706.; Gimsing P., Melgaard B., Andersen K., Vilstrup H., Hippe E. Vitamin B-12 and Folate Function in Chronic Alcoholic Men with Peripheral Neuropathy and Encephalopathy. J Nutr. 1989;119(3):416–424. https://doi.org/10.1093/jn/119.3.416.; Masaki T., Mochizuki H., Matsushita S., Yokoyama A., Kamakura K., Higuchi S. Association of aldehyde dehydrogenase-2 polymorphism with alcoholic polyneuropathy in humans. Neurosci Lett. 2004;363(3):288–290. https://doi.org/10.1016/j.neulet.2004.04.009.; Hammoud N., Jimenez-Shahed J. Chronic Neurologic Effects of Alcohol. Clin Liver Dis. 2019;23(1):141–155. https://doi.org/10.1016/j.cld.2018.09.010.; Dervaux A., Laqueille X. Thiamine (vitamin B1) treatment in patients with alcohol dependence. Presse Med. 2017;46(2):165–171. https://doi.org/10.1016/j.lpm.2016.07.025.; Пизова Н.В. Маски алкогольной полиневропатии. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):114–118. https://doi.org/10.14412/2074-2711-2020-2-114-118.; Koike H., Mori K., Misu K., Hattori N., Ito H., Hirayama M., Sobue G. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology. 2001;56(12):1727–1732. https://doi.org/10.1212/wnl.56.12.1727.; Левин О.С. Полиневропатии: клиническое руководство. М.: МИА; 2011. 469 с.; Курушина О.В., Барулин А.Е., Черноволенко Е.П. Алкогольная полинейропатия: пути диагностики и терапии. Медицинский совет. 2019;(1):58–63. https://doi.org/10.21518/2079-701X-2019-1-58-63.; Briani C., Argyriou A.A., Izquierdo C., Velasco R., Campagnolo M., Alberti P. et al. Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. J Peripher Nerv Syst. 2014;19: 299–306. https://doi.org/10.1111/jns.12097.; Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6): 772–781. https://doi.org/10.1002/ana.24951.; Geber C., Breimhorst M., Burbach B., Egenolf C., Baier B., Fechir M. et al. Pain in chemotherapy-induced neuropathy — more than neuropathic? Pain. 2013;154(12):2877–2887. https://doi.org/10.1016/j.pain.2013.08.028.; Kautio A.L., Haanpaa M., Kautiainen H., Kalso E., Saarto T. Burden of chemotherapy-induced neuropathy — a cross-sectional study. Support Care Cancer. 2011;19:1991–1996. https://doi.org/10.1007/s00520-010-1043-2.; Hsu H.T., Wu L.M., Lin P.C., Juan C.H., Huang Y.Y., Chou P.L., Chen J.L. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: a cross-sectional study. Medicine (Baltimore). 2020;99:e19029. https://doi.org/10.1097/MD.0000000000019029.; Seretny M., Currie G.L., Sena E.S., Ramnarine S., Grant R., MacLeod M. R. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020.; Sommer C., Geber C., Young P., Forst R., Birklein F., Schoser B. Polyneuropathies. Dtsch Arztebl Int. 2018;115(6):83–90. https://doi.org/10.3238/arztebl.2018.083.; Vilholm O.J., Christensen A.A., Zedan A.H., Itani M. Drug‐induced peripheral neuropathy. Basic Clin Pharmacol Toxicol. 2014;115(2):185–192. https://doi.org/10.1111/bcpt.12261.; Jones M.R., Urits I., Wolf J., Corrigan D., Colburn L., Peterson E. et al. Drug-Induced Peripheral Neuropathy: A Narrative Review. Curr Clin Pharmacol. 2020;15(1):38–48. https://doi.org/10.2174/1574884714666190121154813.; Green S., Holton A. Drug-induced peripheral neuropathy. Adverse Drug React. Bull. 2016;300(1):1159–1162. https://doi.org/10.1097/FAD.0000000000000020.; Ma J., Kavelaars A., Dougherty P.M., Heijnen C.J. Beyond symptomatic relief for chemotherapy-induced peripheral neuropathy: Targeting the source. Cancer Wiley-Blackwell. 2018;124(11):2289–2298. https://doi.org/10.1002/cncr.31248.; Wu C., Tcherny-Lessenot S., Dai W., Wang Y., Kechemir H., Gandhi S. et al. Assessing the risk for peripheral neuropathy in patients treated with dronedarone compared with that in other antiarrhythmics. Clin Ther. 2018;40(3):450–455. https://doi.org/10.1016/j.clinthera.2018.01.015.; Svendsen T. de K., Nørregaard H.P., García R.L. A., Andersen L., Hallas J., Hein S. S, Gaist D. Statins and polyneuropathy revisited: Case-control study in Denmark, 1999-2013. Br J Clin Pharmacol. 2017;83(9): 2087–2095. https://doi.org/10.1111/bcp.13298.; Duffy L.F., Daum F., Fisher S.E., Selman J., Vishnubhakat S.M., Aiges H.W. et al. Peripheral neuropathy in Crohn’s di sease patients treated with metronidazole. Gastroenterology. 1985;88(3):681–684. https://doi.org/10.1016/0016-5085(85)90137-4.; Toth C., Breithaupt K., Ge S., Duan Y., Terris J.M., Thiessen A. et al. Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease. Ann Neurol. 2010;68(1):28–36. https://doi.org/10.1002/ana.22021.; Cossu G., Ceravolo R., Zibetti M., Arca R., Ricchi V., Paribello A. et al. Levodopa and neuropathy risk in patients with Parkinson disease: Effect of COMT inhibition. Park Relat Disord. 2016;27:81–84. https://doi.org/10.1016/j.parkreldis.2016.04.016.; Merola A., Romagnolo A., Zibetti M., Bernardini A., Cocito D., Lopiano L. Peripheral neuropathy associated with levodopa-carbidopa intestinal infusion: A long-term prospective assessment. Eur J Neurol. 2016;23(3):501–509. https://doi.org/10.1111/ene.12846.; Ceravolo R., Cossu G., Bandettini di Poggio M., Santoro L., Barone P., Zibetti M. et al. Neuropathy and levodopa in Parkinson’s disease: Evidence from a multicenter study. Mov Disord. 2013;28(10):1391–1397. https://doi.org/10.1002/mds.25585.; Callaghan B.C., Kerber K.A., Lisabeth L.L., Morgenstern L.V., Longoria R., Rodgers A. et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurology. 2014;71(9):1143–1149. https://doi.org/10.1001/jamaneurol.2014.1279.; Johannsen L., Smith T., Havsager A.M., Madsen C., Kjeldsen M.J., Dalsgaard N.J. et al. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neur Dis. 2001;3(2):47–52. https://doi.org/10.1097/00131402-200112000-00001.; Lubec D., Mullbacher W., Finsterer J., Mamoli B. Diagnostic work-up in peripheral neuropathy: an analysis of 171 cases. Post Med J. 1999;75(890):723–727. https://doi.org/10.1136/pgmj.75.890.723.; Dyck P.J., Oviatt K.F., Lambert E.H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol. 1981;10(3):222–226. https://doi.org/10.1002/ana.410100304.; Notermans N.C., Wokke J.H., Franssen H., van der Graaf Y., Vermeulen M., van den Berg LH. et al. Chronic idiopathic polyneuropathy presenting in middle or old age: a clinical and electrophysiological study of 75 patients. J Neurol Neurosurg Psychiatry. 1993;56(10):1066–1071. https://doi.org/10.1136/jnnp.56.10.1066.; Singer M.A., Vernino S.A., Wolfe G.I. Idiopathic neuropathy: new paradigms, new promise. J Peripher Nerv Syst. 2012;17(2 Suppl.):43–49. https://doi.org/10.1111/j.1529-8027.2012.00395.x.; Hughes R.A., Umapathi T., Gray I.A., Gregson N.A., Noori M., Pannala A.S. et al. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain. 2004;127(8):1723–1730. https://doi.org/10.1093/brain/awh192.; Ibrahim A., Jude E., Langton K., Martinez-De Jesus F.R., Harkless L.B., Gawish H. et al. International Diabetes Federation. Clinical Practice Recommendation on the Diabetic Foot: A guide for health care professionals: International Diabetes Federation. 2017. Available at: https://endocrinologie.usmf.md/sites/default/files/inline-files/IDF_DF_Foot_CPR_2017_Final%20%281%29.pdf.; Reed L.J., DeBusk B. G., Gunsalus I.C., Hornberger C.S. Crystalline α-lipoic acid: A catalytic agent associated with pyruvate dehydrogenase. Science. 1951;114(2952):93–94. https://doi.org/10.1126/science.114.2952.93.; Salehi B., Yılmaz B.Y., Antika G., Boyunegmez T.T., Fawzi M.M., Lobine D. et al. Insights on the Use of alpha-Lipoic Acid for Therapeutic Purposes. Biomolecules. 2019;9(8):356. https://doi.org/10.3390/biom9080356.; Singh U., Jialal I. Retracted: Alpha-lipoic acid supplementation and diabetes. Nutr Rev. 2008;66(11):646–657. https://doi.org/10.1111/j.1753-4887.2008.00118.x.; Maglione E., Marrese C., Migliaro E., Marcuccio F., Panico C., Salvati C. et al. Increasing bioavailability of (R)-alpha-lipoic acid to boost antioxidant activity in the treatment of neuropathic pain. Acta BioMedica Atenei Parm. 2015;86(3):226–233. Available at: https://pubmed.ncbi.nlm.nih.gov/26694149.; Packer L., Cadenas E. Lipoic acid: Energy metabolism and redox regulation of transcription and cell signaling. J Clin Biochem Nutr. 2010;48(1):26–32. https://doi.org/10.3164/jcbn.11-005FR.; Konrad D., Somwar R., Sweeney G., Yaworsky K., Hayashi M., Ramlal T., Klip A. The antihyperglycemic drug alpha-lipoic acid stimulates glucose uptake via both GLUT4 translocation and GLUT4 activation: Potential role of p38 mitogen-activated protein kinase in GLUT4 activation. Diabetes. 2001;50(6):1464–1471. https://doi.org/10.2337/diabetes.50.6.1464.; Chen W.-L., Kang C.-H., Wang S.-G., Lee H.-M. α-Lipoic acid regulates lipid metabolism through induction of sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. Diabetologia. 2012;55:1824–1835. https://doi.org/10.1007/s00125-012-2530-4.; Gorąca A., Huk-Kolega H., Piechota A., Kleniewska P., Ciejka E., Skibska B. Lipoic acid – biological activity and therapeutic potential. Pharmacol Rep. 2011;63(4):849–858. https://doi.org/10.1016/S1734-1140(11)70600-4.; Han D., Handelman G., Marcocci L., Sen C.K., Roy S., Kobuchi H. et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Biofactors. 1997;6(3):321–338. https://doi.org/10.1002/biof.5520060303.; Shay K.P., Moreau R.F., Smith E.J., Smith A.R., Hagen T.M. Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Biochim Biophys Acta. 2009;1790(10):1149–1160. https://doi.org/10.1016/j.bbagen.2009.07.026.; Ou P., Tritschler H.J., Wolff S.P. Thioctic (lipoic) acid: A therapeutic metalchelating antioxidant? Biochem Pharmacol. 1995;50(1):123–126. https://doi.org/10.1016/0006-2952(95)00116-H.; Stevens M.J., Obrosova I., Cao X., Van Huysen C., Greene D.A. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes. 2000; 49(6):1006–1015. https://doi.org/10.2337/diabetes.49.6.1006.; van Dam P.S., van Asbeck B.S., Van Oirschot J.F., Biessels G.J., Hamers F.P., Marx J.J. Glutathione and alpha-lipoate in diabetic rats: nerve function, blood flow and oxidative state. Eur J Clin Invest. 2001;31(5):417–424. https://doi.org/10.1046/j.1365-2362.2001.00832.x.; Ford I., Cotter M.A., Cameron N.E., Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism. 2001;50(8):868–875. https://doi.org/10.1053/meta.2001.24914.; Sun L., Chen Y., Wang X., Li X., Xue B., Qu L. et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol. 2012;84(7):961–973. https://doi.org/10.1016/j.bcp.2012.07.005.; Heitzer T., Finckh B., Albers S., Krohn K., Kohlschütter A., Meinertz T. Benefficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med. 2001;31(1):53–61. https://doi.org/10.1016/s0891-5849(01)00551-2.; Castro M.C., Villagarcía H.G., Massa M.L., Francini F. Alpha-lipoic acid and its protective role in fructose induced endocrine-metabolic disturbances. Food Funct. 2019;10(1):16–25. https://doi.org/10.1039/C8FO01856A.; Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: A critical review. Treat Endocrino. 2004;3:173–179. https://doi.org/10.2165/00024677-200403030-00005.; Henriksen E.J. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic Boil Med. 2006;40(1):3–12. https://doi.org/10.1016/j.freeradbiomed.2005.04.002.; Reljanovic M., Reichel G., Rett K., Lobisch M., Schuette K., Möller W. et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999;31(3):171–179. https://doi.org/10.1080/10715769900300721.; Ziegler D., Hanefeld M., Ruhnau R.J., Hasche H., Lobisch M., Schütte K. et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care. 1999;22(8):1296–1301. https://doi.org/10.2337/diacare.22.8.1296.; Терещенко И.В. Берлитион – залог успеха в лечении полинейропатии. Поликлиника. 2014;(5):21–24. Режим доступа: https://www.poliklin.ru/imagearticle/201405(1)/21-24.pdf.; Бойко А.Н., Камчатнов П.Р. Возможности применения берлитиона при диабетической полинейропатии. Справочник поликлинического врача. 2013;(10):42–45. Режим доступа: https://omnidoctor.ru/library/izdaniyadlya-vrachey/spravochnik-poliklinicheskogo-vracha/spv2013/spv2013_10/vozmozhnosti-primeneniya-berlitiona-pri-diabeticheskoypolineyropatii.; Данилов А.Б., Пилипович А.А. Тиоктовая кислота: современная терапия диабетической полинейропатии. Эффективная фармакотерапия. 2017;(2):14–20. Режим доступа: https://umedp.ru/articles/tioktovaya_kislota_sovremennaya_terapiya_diabeticheskoy_polinevropatii.html?sphrase_id=74098.; Воробьева О.В. Клинический разбор пациента с коморбидными неврологическими осложнениями сахарного диабета в практике амбулаторного врача: взгляд невролога. Трудный пациент. 2018;16(11):35–39. https://doi.org/10.24411/2074-1995-2018-10028.; Дадашева М.Н., Горенков Р.В., Дадашева К.Н. Ранняя диагностика и современные аспекты лечения диабетической полинейропатии. Трудный пациент. 2020;18(4):6–9. https://doi.org/10.24411/2074-1995-2020-10022.; Ковражкина Е.А. Аксональные полинейропатии: патогенез и лечение. Журнал неврологии и психиатрии им. C.C. Корсакова. 2013;113(6):22–25. Режим доступа: https://mediasphera.ru/issues/zhurnal-nevrologii-ipsikhiatrii-im-s-s-korsakova/2013/6/downloads/ru/031997-7298201364.; Храмилин В.Н., Чазова Т.Е. Опыт клинического применения Берлитиона при диабетической периферической полинейропатии. Сахарный диабет. 2001;4(4):46–51. https://doi.org/10.14341/DM2001446-51.; Зиновьева О.Е. Антиоксидантная терапия диабетической нейропатии. РМЖ. 2006;(9):647. Режим доступа: https://rmj.ru/articles/obshchie-stati/Antioksidantnaya_terapiya_diabeticheskoy_nevropatii.; Collins M.P., Hadden R.D. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017;13:302–316. https://doi.org/10.1038/nrneurol.2017.42.; Üçeyler N., Rogausch J.P., Toyka K.V., Sommer C. Differential expression of cytokines in painful and painless neuropathies. Neurology. 2007;69(1):42–49. https://doi.org/10.1212/01.wnl.0000265062.92340.a5.; Finnerup N.B., Attal N., Haroutounian S., McNicol E., Baron R., Dworkin R. et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. https://doi.org/10.1016/S1474-4422(14)70251-0.; https://www.med-sovet.pro/jour/article/view/6542

الاتاحة: https://www.med-sovet.pro/jour/article/view/6542
https://doi.org/10.21518/2079-701X-2021-19-134-146

المؤلفون: Yarema, N. I., Khomitska, A. I., Savchenko, I. P., Radetska, L. V., Naumova, L. V., Kotsyuba, O. I.

المصدر: Achievements of Clinical and Experimental Medicine; No. 3 (2017) ; Достижения клинической и экспериментальной медицины; № 3 (2017) ; Здобутки клінічної і експериментальної медицини; № 3 (2017) ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2017.v1.i3

مصطلحات موضوعية: stable ischemic heart disease, left ventricle diastolic dysfunction, diabetes mellitus type 2, diabetic neuropathy of the lower extremities, oxygenation of arterial and venous blood, alpha-lipoic acid, стабильная ишемическая болезнь сердца, диастолическая дисфункция левого желудочка, сахарный диабет 2 типа, диабетическая полинейропатия нижних конечностей, оксигенация артериальной и венозной крови, альфа-липоевая кислота, стабільна ішемічна хвороба серця, діастолічна дисфункція лівого шлуночка, цукровий діабет 2 типу, діабетична полінейропатія нижніх кінцівок, оксигенація артеріальної та венозної крові, альфа-ліпоєва кислота

وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

Relation: https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/7954/7668; https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/7954/8793; https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/7954/8794; https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/7954; https://repository.tdmu.edu.ua//handle/123456789/13745

الاتاحة: https://repository.tdmu.edu.ua//handle/123456789/13745
https://ojs.tdmu.edu.ua/index.php/zdobutky-eks-med/article/view/7954
https://doi.org/10.11603/1811-2471.2017.v1.i3.7954

المؤلفون: V. A. Golovacheva, В. А. Головачева

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 12, No 6 (2020); 96-103 ; Неврология, нейропсихиатрия, психосоматика; Vol 12, No 6 (2020); 96-103 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2020-6

مصطلحات موضوعية: тиоктовая кислота, alcoholic polyneuropathy, diagnosis, treatment, alpha-lipoic acid, thioctic acid, алкогольная полиневропатия, диагностика, лечение, альфа-липоевая кислота

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1477/1154; Зиновьева ОЕ, Казанцева ЮФ. Патогенетическая терапия дисметаболических полиневропатий. Трудный пациент. 2011;(7):38-45. Доступно по ссылке: http://t-pacient.ru/articles/6685/; Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments [published correction appears in: Diabetes Care. 2010 Dec;33(12):2725]. Diabetes Care. 2010;33(10):2285-93. doi:10.2337/dc10-1303; Julian T, Glascow N, Syeed R, Zis P. Alcohol-related peripheral neuropathy: a systematic review and meta-analysis. J Neurol. 2019 Dec;266(12):2907-19. doi:10.1007/s00415-018-9123-1; Зиновьева ОЕ, Емельянова АЮ. Алкогольная полиневропатия: клинико-патогенетические варианты, принципы диагностики и лечения. Эффективная фармакотерапия. Неврология. 2015;2(13):28-36. Доступно по ссылке: https://umedp.ru/articles/alkogolnaya_polinevropatiya_klinikopatogeneticheskie_varianty_printsipy_diagnostiki_i_lecheniya.html?sphrase_id=57962 (In Russ.)].; Yang H, Sloan G, Ye Y, et al. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front Endocrinol (Lausanne). 2020 Jan 17;10:929. doi:10.3389/fendo.2019.00929. eCollection 2019.; Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-54. doi:10.2337/dc16-2042; Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993;43:817-24. doi:10.1212/WNL.43.4.817; Kasznicki J. Advances in the diagnosis and management of diabetic distal symmetric polyneuropathy. Arch Med Sci. 2014;10(2):345- 54. doi:10.5114/aoms.2014.42588; Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-25. doi:10.2337/diabetes.54.6.1615; Andersen ST, Witte DR, Dalsgaard EM, et al. Risk factors for incident diabetic polyneuropathy in a cohort with screen-detected type 2 diabetes followed for 13 years: ADDITIONDenmark. Diabetes Care. 2018;41:1068-75. doi:10.2337/dc17-2062; Shillo P, Sloan G, Greig M, et al. Painful and painless diabetic neuropathies: what is the difference? Curr Diabetes Rep. 2019;19:32. doi:10.1007/s11892-019-1150-5; Междунаpодная статистическая класcификация болезней и пpоблем, связанных со здоpовьем. Десятый пеpесмотp (МКБ-10). Женева; 1995. Доступно по ссылке: https://www.who.int/classifications/icd/ICD10Volume2_en_2010.pdf; Строков ИА, Фокина АС, Строков КИ, Дроконова ОО. Современные принципы диагностики и лечения диабетической полинейропатии. Медицинский совет. 2014;(5):38-43. doi:10.21518/2079-701X2014-5-38-43; Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296-313. doi:10.1016/j.neuron.2017.02.005; Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol. 2010;17:903-12; e44-9. doi:10.1111/j.1468-1331.2010.03023.x; Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes. 2007;56:2148-54. doi:10.2337/db07-0285; Inceu GV, Veresiu IA. Measurement of current perception thresholds using the Neurometer((R)) – applicability in diabetic neuropathy. Clujul Med. 2015;88:449-52. doi:10.15386/cjmed-491; Verghese J, Bieri PL, Gellido C, et al. Peripheral neuropathy in young-old and old-old patients. Muscle Nerve. 2001 Nov;24(11):1476- 81. doi:10.1002/mus.1171; Koike H, Iijima M, Sugiura M, et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol. 2003 Jul;54(1):19-29. doi:10.1002/ana.10550; Koike H, Mori K, Misu K, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status. Neurology. 2001 Jun 26;56(12):1727-32. doi:10.1212/wnl.56.12.1727; Ammendola A, Tata MR, Aurilio C, et al. Peripheral neuropathy in chronic alcoholism: a retrospective cross-sectional study in 76 subjects. Alcohol Alcohol. 2001 May-Jun;36(3):271- 5. doi:10.1093/alcalc/36.3.271; Tugnoli V, Eleopra R, De Grandis D. Hyperhidrosis and sympathetic skin response in chronic alcoholic patients. Clin Auton Res. 1999 Feb;9(1):17-22. doi:10.1007/BF02280692; Vittadini G, Buonocore M, Colli G, et al. Alcoholic polyneuropathy: a clinical and epidemiological study. Alcohol Alcohol. 2001 Sep-Oct;36(5):393-400. doi:10.1093/alcalc/36.5.393; Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;6(6):CD007543. doi:10.1002/14651858.CD007543.pub2. Epub 2012 Jun 13.; Ang L, Jaiswal M, Martin C, Pop-Busui R. Glucose control and diabetic neuropathy: lessons from recent large clinical trials. Curr Diab Rep. 2014;14(9):528. doi:10.1007/s11892-014-0528-7; Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36:2456-65. doi:10.2337/dc12-1964; Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414(6865):813-20. doi:10.1038/414813a; Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia. 1995 Dec;38(12):1425-33. doi:10.1007/BF00400603; Парфенов ВА, Головачева ВА, Фадеев ВВ и др. Оптимизация ведения пациентов с диабетической полиневропатией с помощью междисциплинарного подхода. Медицинский совет. 2017;(1S):71-9. doi:10.21518/2079-701X-2017-0-71-79; Строков ИА, Строков КИ, Афонина ЖА. Патогенетическая терапия диабетической полиневропатии. Лечащий врач. 2008;(3):10-6. Доступно по ссылке: https://www.lvrach.ru/2008/03/4906152/; Строков ИА, Фокина АС, Головачева ВА. Следует ли лечить диабетическую полиневропатию альфа-липоевой кислотой? Эффективная фармакотерапия. Неврология и психиатрия. 2013;32(3):40-6. Доступно по ссылке: https://umedp.ru/articles/sleduet_li_lechit_diabeticheskuyu_polinevropatiyu_alfalipoevoy_kislotoy.html; Мелешкевич ТА, Лучина ЕИ, Лукашова МЕ. Опыт применения препарата Мильгамма в условиях эндокринологического отделения. Русский медицинский журнал. 2010;14:907. Доступно по ссылке: https://www.rmj.ru/articles/endokrinologiya/Opyt_primeneniya_preparata_Milygamma__v_usloviyah_endokrinologicheskogo_otdeleniya/#ixzz6MztP0tSo; Луцкий ИС, Лютикова ЛВ, Луцкий ЕИ. Витамины группы В в неврологической практике. Международный неврологический журнал. 2008;(2):89-93. Доступно по ссылке: http://www.mif-ua.com/archive/article/7441; Ахмеджанова ЛТ, Баринов АН, Солоха ОА и др. Диабетическая полиневропатия: современный алгоритм ведения пациентов. Неврология, нейропсихиатрия, психосоматика. 2019;11(2):100-5. doi:10.14412/2074-2711-2019-2-100-105; Ziegler D, Reljanovic M, Mehnert H, Gries FA. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials. Exp Clin Endocrinol Diabetes. 1999;107(7):421-30. doi:10.1055/s-0029-1212132; Ametov AS, Barinov A, Dyck PJ, et al; SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar;26(3):770-6. doi:10.2337/diacare.26.3.770; Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2):114-21. doi:10.1111/j.1464-5491.2004.01109.x; Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503; Головачева ВА, Зиновьева ОЕ. Диабетическая полинейропатия: от науки к практике. Медицинский Совет. 2015;(7):18- 22. doi:10.21518/2079-701X-2015-7-18-22; Peters TJ, Kotowicz J, Nyka W, et al. Treatment of alcoholic polyneuropathy with vitamin B complex: a randomised controlled trial. Alcohol Alcohol. 2006 Nov-Dec;41(6):636-42. doi:10.1093/alcalc/agl058; Fennelly J, Frank O, Baker H, Leevy CM. Peripheral neuropathy of the alcoholic: I, aetiological role of aneurin and other B-complex vitamins. Br Med J. 1964 Nov 21;2(5420):1290-2. doi:10.1136/bmj.2.5420.1290; Калинченко СЮ, Ворслов ЛО, Курникова ИА, Гадзинва ИВ. Современный взгляд на возможности применения альфа-липоевой кислоты. Эффективная фармакотерапия. 2012;(1):54- 8. Доступно по ссылке: https://umedp.ru/articles/sovremennyy_vzglyad_na_vozmozhnosti_primeneniya_alfalipoevoy_kisloty.html; Abdulrazzaq AM, Badr M, Gammoh O, et al. Hepatoprotective Actions of Ascorbic Acid, Alpha Lipoic Acid and Silymarin or Their Combination Against AcetaminophenInduced Hepatotoxicity in Rats. Medicina (Kaunas). 2019 May 21;55(5):181. doi:10.3390/medicina55050181; Курушина ОВ, Барулин АЕ, Черноволенко ЕП. Алкогольная полинейропатия: пути диагностики и терапии. Медицинский cовет. 2019;(1):58-63. doi:10.21518/2079-701X-2019-1-58-63; Пизова НВ. «Маски» алкогольной полиневропатии. Неврология, нейропсихиатрия, психосоматика. 2020;12(2):114-8. doi:10.14412/2074-2711-2020-2-114-118; https://nnp.ima-press.net/nnp/article/view/1477

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1477
https://doi.org/10.14412/2074-2711-2020-6-96-103

المؤلفون: L. Akhmedzhanova T., T. Belyakova A., Yu. Podkovko A., Yu. Shor M., Л. Ахмеджанова Т., Т. Белякова А., Ю. Подковко А., Ю. Шор М.

المصدر: Meditsinskiy sovet = Medical Council; № 21 (2019); 94-102 ; Медицинский Совет; № 21 (2019); 94-102 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-21

مصطلحات موضوعية: cardiac autonomic neuropathy, diabetic polyneuropathy, cardiovascular tests, treatment of diabetic polyneuropathy, alpha-lipoic acid, Berlithion, кардиальная автономная невропатия, диабетическая полиневропатия, кардиоваскулярные тесты, лечение диабетической полиневропатии, альфа-липоевая кислота, Берлитион

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5480/4999; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.) Клинические рекомендации «Алгоритмы специализированной медицинской помощи больным сахарным диабетом». 9-й выпуск. Москва; 2019;22(S1). Режим доступа: http://webmed.irkutsk.ru/doc/pdf/algosd.pdf.; Azmi Sh., Petropoulos I.N., Ferdousi M., Ponirakis G., Alam U., Malik R.A. An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy [version 1; peer review: 3 approved]. F1000Res. 2019;8(F1000 Faculty Rev):186. doi:10.12688/f1000research.17118.1.; Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. 2-е изд., пере- раб. и доп. М.: ООО «МИА»; 2011.301 с.; Vučković-Rebrina S., Barada A., Smirčić- DuvnjakL. Diabetic Autonomic Neuropathy. Diabetologia Croatica. 2013;42(3):73–79. Available at: http://www.idb.hr/diabetologia/13no3-2.pdf.; Haq T., Ahmed T., Latif Z.A., Sayeed M.A., Ashrafuzzaman S.M. Cardiac autonomic neuropathy in patients with type 2 diabetes mellitus having peripheral neuropathy: A crosssectional study. Diabetes Metab Syndr. 2019;13(2):1523–1528. doi:10.1016/j.dsx.2019.03.015.; Dewanjee S., Das S., Das A.K., Bhattacharjee N., Dihingia A., Dua T.K., et al. Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets. Eur J Pharmacol. 2018;833:472–523. doi:10.1016/j.ejphar.2018.06.034.; Spallone V. Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet. Diabetes Metab J. 2019;43(1):3–30. doi:10.4093/dmj.2018.0259.; Grewal A.S., Bhardwaj S., Pandita D., Lather V., Sekhon B.S. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases. Mini Rev. Med Chem. 2016;16(2):120–162. doi:10.2174/1389557515666150909143737.; Bonete G., Dias B.A.L., Leandro D.A.M., Fernande A.N., Pereira C.H., Ribeiro C.T., at al. Impaired Heart Rate Variability, Valsalva and 30:15 Ratio Indexes Are Associated With Reduced Submaximal Exercise Capacity in Subjects With Diabetes Mellitus. Diabetes Res Clin Pract. 2019;155:107813. doi:10.1016/j.diabres.2019.107813.; Serhiyenko V.A., Serhiyenko A.A. Cardiac autonomic neuropathy: Risk factors, diagnosis and treatment. World J Diabetes. 2018;9(1):1–24. doi:10.4239/wjd.v9.i1.1.; Fisher V.L., Tahrani A.A. Cardiac autonomic neuropathy in patients with diabetes mellitus: current perspectives. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017;10:419–434. doi:10.2147/DMSO.S129797.; Hillis Gr.S., Hata J., Woodward M., Perkovic V., Arima H., Chow C.K., et al. Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. J Am Heart Assoc. 2012;1(5):e002832. doi:10.1161/JAHA.112.002832.; Vinik A., Erbas T., Casellini C.M. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4(1):4–18. doi:10.1111/jdi.12042.; Gibbons C.H., Schmidt P., Biaggioni I., Frazier- Mills C., Freeman R., Isaacson S., et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–1582. doi:10.1007/s00415-016-8375-x.; Bissinger A. Cardiac Autonomic Neuropathy: Why Should Cardiologists Care about That? J Diabetes Res. 2017;2017:5374176. doi:10.1155/2017/5374176.; Janovsky C.C., Rolim L.C., de Sa J.R., Poyares D., Tufik S., Silva A.B., Dib S.A. Cardiovascular autonomic neuropathy contributes to sleep apnea in young and lean type 1 diabetes mellitus patients. Front Endocrinol (Lausanne). 2014;5:119. doi:10.3389/fendo.2014.00119.; Agashe S., Petak S. Cardiac Autonomic Neuropathy in Diabetes Mellitus. Methodist Debakey Cardiovasc J. 2018;14(4):251–256. doi:10.14797/mdcj-14-4-251.; Валеева Ф.В., Шайдуллина М.Р. Диагностика диабетической автономной кардиальной нейропатии у больных сахарным диабетом 1 типа. Сахарный диабет. 2009;(4):56–60. Режим доступа: https://elibrary.ru/item.asp?id=13333729.; Gulichsen El., Fleischer J., Ejskjaer N., Eldrup Eb., Tarnow L. Screening for Diabetic Cardiac Autonomic Neuropathy Using a New Handheld Device. J Diabetes Sci Technol. 2012;6(4):965–972. doi:10.1177/193229681200600430.; Баринов А.Н. Вегетативная невропатия при сахарном диабете и метаболическом синдроме: клинические проявления, диагностика и лечение. Эффективная фармакотерапия. 2017;(2):40–52. Режим доступа: https://umedp.ru/articles/vegetativnaya_nevropatiya_pri_sakharnom_diabete_i_metabolicheskom_sindrome_klinicheskie_proyavleniya.html?sphrase_id=40778.; Gandhi R.A., Marques J.L.B., Selvarajah D., Emery C.J., Tesfaye S. Painful Diabetic Neuropathy Is Associated With Greater Autonomic Dysfunction Than Painless Diabetic Neuropathy. Diabetes Care. 2010;33(7):1585–1590. doi:10.2337/dc09-2314.; Сосина В.Б., Захаров В.В., Строков И.А., Вахнина Н.В. Когнитивные нарушения при сахарном диабете. Неврология, нейропсихиатрия, психосоматика. 2017;9(1):90–95. Режим доступа: https://nnp.ima-press.net/nnp/article/view/704?locale=ru_RU.; Kodl C.T., Seaquist E.R. Cognitive Dysfunction and Diabetes Mellitus. Endocr Rev. 2008;29(4):494–511. doi:10.1210/er.2007-0034.; Pop-Busui R., Boulton A.J., Feldman E.L., Bril V., Freeman R., Ziegler D., et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042.; Pop-Busui R., Evans G.W., Gerstein H.C., Fonseca V., Fleg J.L., Hoogwerf B.J., et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33(7):1578–1584. doi:10.2337/dc10-0125.; Esposito K., Giugliano D. Mediterranean diet and type 2 diabetes, Diabetes Metab Res Rev. 2014;30(S1):34–40. doi:10.1002/dmrr.2516.; Ziegler D., Hanefeld M., Ruhnau K.J., Meissner H.P., Lobisch M., Schütte K., Gries F.A. Treatment of symptomatic diabetic peripheral neuropathy with the antioxydant alpha-lypoic acid. (ALADIN study group). Diabetologica. 1995;38:1425–1433. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8786016.; Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a meta-analysis. Diabet Med. 2004;21:114–121. Available at: https://www.ncbi.nlm.nih.gov/pubmed/14984445.; Аметов А.С. Рекомендации по лечению диабетической невропатии в России. РМЖ. 2010;14:869–878. Режим доступа: https://www.rmj.ru/articles/endokrinologiya/Rekomendacii_po_lecheniyu__diabeticheskoy_nevropatii_v_Rossii/; Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha lipoic Acid for symptomaticperipheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279. doi:10.1155/2012/456279.; Ziegler D., Schatz H., Conrad F., Gries F.A., Ulrich H., Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care. 1997;20(3):369–373. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9051389.; Akbari M., Ostadmohammadi V., Tabrizi R., Mobini M., Lankarani K.B., Moosazadeh M., et al. The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Nutr Metab. 2018;15:39. doi:10.1186/s12986-018-0274-y.; Строков И.А., Ахмеджанова Л.Т., Фокина А.С., Баринов А.Н. Патогенетическая терапия диа- бетической полиневропатии альфа-липоевой кислотой с точки зрения доказательной медицины. Эффективная фармакотерапия. 2019;(4):32–40. Режим доступа: http://umedp.ru/upload/iblock/022/effektivnaya_farmakoterapiya_nevrologiya_i_psikhiatriya_1_2019_VAK.pdf.; Jun J.E., Lee S.E., Choi M.S., Park S.W., Hwang Y.C., Kim J.H. Clinical factors associated with the recovery of cardiovascular autonomic neuropathy in patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2019;18:29. doi:10.1186/s12933-019-0830-4.; Spallone V., Bellavere F., Scionti L., Maule S., Quadri R., Bax G., et al. Recommendations for the use of cardiovascular tests in diagnosing diabetic autonomic neuropathy. Nutr Metab Cardiovas Dis. 2011;21(1):69–78. doi:10.1016/j.numecd.2010.07.005.; https://www.med-sovet.pro/jour/article/view/5480

الاتاحة: https://www.med-sovet.pro/jour/article/view/5480
https://doi.org/10.21518/2079-701X-2019-21-94-102

المؤلفون: L. Akhmedzhanova T., A. Isaikin I., O. Chernenko A., Yu. Shor M., D. Merkulova M., M. Kachanovsky S., N. Shcheglova S., Л. Ахмеджанова Т., А. Исайкин И., О. Черненко А., Ю. Шор М., Д. Меркулова М., М. Качановский С., Н. Щеглова С.

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 11, No 4 (2019); 160-165 ; Неврология, нейропсихиатрия, психосоматика; Vol 11, No 4 (2019); 160-165 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2019-4

مصطلحات موضوعية: diabetic cervicobrachial radiculoplexopathy, diabetic lumbosacral radiculoplexopathy, alpha-lipoic acid, диабетическая шейно-плечевая радикулоплексопатия, диабетическая пояснично-крестцовая радикулоплексопатия, альфа-липоевая кислота

وصف الملف: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1228/982; Глобальный доклад по диабету. Всемирная организация здравоохранения. 2018 https://apps.who.int/iris/handle/10665/275388; International Diabetes Federation. IDF Diabetes Atlas – 8th edition: key messages. IDF https://diabetesatlas.org/key-messages.html; Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-154. doi:10.2337/dc16-2042.; Dyck PJ. Radiculoplexus neuropathies: diabetic and nondiabetic varieties. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. 4th ed. Vol. 2. Philadelphia: Elsevier Saunders; 2005. P. 1993-2037.; Llewelyn JG, Tomlinson D, Thomas PK. Diabetic neuropathies. In: Dyck PJ, Thomas PK, editors. Peripheral neuropathy. 4th ed. Vol. 2. Philadelphia: Elsevier Saunders; 2005. P.1951-91.; Горбачева ФЕ, Зиновьева ОЕ, Алексеева МЕ, Щекина РВ. Диабетическая амиотрофия: подходы к лечению. Неврологический журнал. 1997;(2):17-22.; Imtiaz KE, Lekwuwa G, Kaimal N, et al. Elevated cerebrospinal fluid protein in diabetic lumbosacral radiculoplexus neuropathy. QJM. 2012 Nov;105(11):1119-23. doi:10.1093/qjmed/hcr166. Epub 2011 Sep 14.; Raff M, Asbury AK. Ischemic mononeuropathy and mononeuropathy multiplex in diabetes mellitus. N Engl J Med. 1968 Jul 4;279(1):17-21.; Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin Proc. 1997 Dec;72(12): 1123-32.; Massie R, Mauermann ML, Staff NP, et al. Diabetic cervical radiculoplexus neuropathy: a distinct syndrome expanding the spectrum of diabetic radiculoplexus neuropathies. Brain. 2012 Oct;135(Pt 10):3074-88. doi:10.1093/brain/aws244.; Katz JS, Saperstein DS, Wolfe G, at al. Cervicobrachial involvement in diabetic radiculoplexopathy. Muscle Nerve. 2001 Jun;24(6): 794-8.; Gupta G, Massie R, Doherty T, et al. Diabetic cranio-cervico-radiculoplexus neuropathy. PM R. 2015 Nov;7(11):1189-1193. doi:10.1016/j.pmrj.2015.05.003. Epub 2015 May 12.; Ахмеджанова ЛТ, Баринов АН, Строков ИА. Диабетические и недиабетические полиневропатии у пациентов с сахарным диабетом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(4): 113-21.; Ng P, Dyck PJ, Laughlin R, et al. Lumbosacral radiculoplexus neuropathy. Incidence and the association with diabetes mellitus. Neurology. 2019 Mar 12;92(11):e1188-e1194. doi:10.1212/WNL.0000000000007020. Epub 2019 Feb 13.; Waldfogel JM, Nesbit SA, Dy SM, Sharma R. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: A systematic review. Neurology. 2017 May 16;88(20):1958-1967. doi:10.1212/WNL.0000000000003882. Epub 2017 Mar 24.; Исайкин АИ, Кавелина ВА, Зиновьева ОЕ, Ахмеджанова ЛТ. Диабетическая проксимальная амиотрофия (клинический случай). Медицинский совет. 2014;(2):46-51.; Kilfoyle D, Kelkar P, Parry GJ. Pulsed methylprednisolone is a safe and effective treatment for diabetic amyotrophy. J Clin Neuromuscul Dis. 2003 Jun;4(4):168-70.; Thaisetthawatkul P, Dyck PJ. Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. Curr Treat Options Neurol. 2010 Mar;12(2):95-9. doi:10.1007/s11940-010-0059-8.; Kawagashirea Y, Watanabe H, Oki Y, et al. Intravenous immunoglobulin therapy markedly ameliorates muscle weakness and severe pain in proximal diabetic neuropathy. J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):899-901.; Tamburin S, Zanette G. Intravenous immunoglobulin for the treatment of diabetic lumbosacral radiculoplexus neuropathy. Pain Med. 2009 Nov;10(8):1476-80. doi:10.1111/j.1526-4637.2009.00704.x. Epub 2009 Sep 25.; Chan YC, Lo YL, Chan ES. Immunotherapy for diabetic amyotrophy. Cochrane Database Syst Rev. 2012 Jun 13; (6):CD006521. doi:10.1002/14651858.CD006521.pub3.; Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003 Mar; 26(3):770-6.; Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxydant alpha-lypoic acid. (ALADIN study group). Diabetologia. 1995 Dec;38(12):1425-33.; Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med. 2004 Feb;21(2): 114-21.; Строков ИА, Ахмеджанова ЛТ, Баринов АН и др. Патогенетическая терапия диабетической полиневропатии альфа-липоевой кислотой с точки зрения доказательной медицины. Эффективная фармакотерапия. 2019;(1):32-40.; Tesfaye S. Boulton AJM, Dyck PJ, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010 Oct;33(10): 2285-93. doi:10.2337/dc10-1303.; Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized doubleblind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res. 1999 Sep;31(3):171-9.; Ziegler D, Low PA, Boulton AJM, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy:the NATHAN-1 trial. Diabetes Care. 2011 Sep;34(9):2054-60. doi:10.2337/dc11-0503. Epub 2011 Jul 20.; https://nnp.ima-press.net/nnp/article/view/1228

الاتاحة: https://nnp.ima-press.net/nnp/article/view/1228
https://doi.org/10.14412/2074-2711-2019-4-160-165

المؤلفون: O. Kotova V., E. Akarachkova S., A. Belyaev A., О. Котова В., Е. Акарачкова С., А. Беляев А.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2019); 40-44 ; Медицинский Совет; № 9 (2019); 40-44 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-9

مصطلحات موضوعية: diabetes mellitus, cognitive functions, neuropathy, alpha-lipoic acid, dipyridamol, сахарный диабет, когнитивные функции, невропатии, альфа-липоевая кислота, дипиридамол

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/3033/2958; Aypak C., Koç A., Yıkılkan H., Görpelioğlu S. Diabetic foot care: self reported practise among patients attending family medicine outpatient clinics. Cumhuriyet Medical Journal. 2012;34(4):423-428.; Biessels G.J., Staekenborg S., Brunner E., Brayne C., Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64-74.; Moheet A., Mangia S., Seaquist E.R. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015 Sep;1353:60-71. doi:10.1111/nyas.12807. Epub 2015 Jul 1.; Mijnhout G.S., Scheltens P., Diamant M., Biessels G.J., Wessels A.M., Simsek S., Snoek F.J., Heine R.J. Diabetic encephalopathy: A concept in need of a definition. Diabetologia. 2006 Jun;49(6):1447-8. Epub 2006 Apr 6.; Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson A.M., Musen G., Ryan C.M., Silvers N., Cleary P., Waberski B., Burwood A., Weinger K., Bayless M., Dahms W., Harth J. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007 May 3;356(18):1842-52.; Reichard, P., Pihl, M., Rosenqvist, U. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10‐year follow up. Diabetologia. 1996;39:1483-1488.; Arbelaez A.M., Semenkovich K., Hershey T. Glycemic extremes in youth with T1DM: the structural and functional integrity of the developing brain. Pediat. Diab. 2013;14:541–553.; Ryan C.M., Geckle M.O. & Orchard T.J. Cognitive efficiency declines over time in adults with type 1 diabetes: effects of micro‐ and macrovascular complications. Diabetologia. 2003;46:940–948.; Perantie D.C., Lim A., Wu J., et al. Effects of prior hypoglycemia and hyperglycemia on cognition in children with type 1 diabetes mellitus. Pediat. Diab. 2008;9:87–95.; Northam E., Rankins D., Lin A., et al. Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diab. Care. 2009;32:445–50.; Ohmann S., Popow C., Rami B., König M., Blaas S., Fliri C., Schober E. Cognitive functions and glycemic control in children and adolescents with type 1 diabetes. Psychol Med. 2010 Jan;40(1):95-103. doi:10.1017/S0033291709005777. Epub 2009 Apr 29.; Nooyens A.C., Baan C.A., Spijkerman A.M., Verschuren W.M. Type 2 diabetes and cognitive decline in middle-aged men and women: the Doetinchem Cohort Study. Diabetes Care. 2010 Sep;33(9):1964-9. doi:10.2337/dc09-2038.Epub 2010 Jun 2.; Kanaya A.M. Change in cognitive function by glucose tolerance status in older adults: a 4‐ year prospective study of the Rancho Bernardo study cohort. Arch Intern Med. 2004;164:1327–1333.; Gregg E.W., Yaffe K., Cauley J.A., et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch. Intern. Med. 2000;160:174–180.; Hassing L., Grant M., Hofer S., et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population‐based study. J. Intl. Neuropsychol. Soc. 2004;10:599–607.; van den Berg E., Reijmer Y.D., de Bresser J., Kessels R.P., Kappelle L.J., Biessels G.J.; Utrecht Diabetic Encephalopathy Study Group. A 4 year follow-up study of cognitive functioning in patients with type 2 diabetes mellitus. Diabetologia. 2010 Jan;53(1):58-65. doi:10.1007/s00125-009-1571-9. Epub 2009 Oct 31.; Hugenschmidt C.E., Lovato J.F., Ambrosius W.T., et al. The cross‐sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the action to control cardiovascular risk in diabetes (ACCORD) trial. Diab. Care. 2014;37:3244–3252.; Patton N., Aslam T., MacGillivray T., et al. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. J. Anat. 2005;206:319–348.; Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 1999 Dec 10;53(9):1937-42.; Manschot S.M., Brands A.M.A., der Grond J., et al. Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes. 2006;55:1106–1113.; Ebady S. Investigation on the relationship between diabetes mellitus type 2 and cognitive impairment. Diab. Res. Clin. Pract. 2009;82:305.; Grodstein F., Wilson R.S., Chen J., et al. Type 2 diabetes and cognitive function in communitydwelling elderly women. Diab. Care. 2001;24:1060–1065.; Ding J., Strachan M.W.J., Reynolds R., et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes. 2010;59:2883.; Kivipelto M., Helkala E.L., Hnninen T., et al. Midlife vascular risk factors and late‐life mild cognitive impairment: a population‐based study. Neurology. 2001;56:1683–1689.; DeCarli C., Miller B.L., Swan G.E., et al. Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study. Arch. Neurol. 2001;58:643–647. 26. McCrimmon R.J., Ryan C.M., Frier B.M. Diabetes and cognitive dysfunction. Lancet. 2012 Jun 16;379(9833):2291-9. doi:10.1016/S0140-6736(12)60360-2. Epub 2012 Jun 9.; Mankovsky B., Zherdova N., van den Berg E., Biessels G.J., de Bresser J. Cognitive functioning and structural brain abnormalities in people with Type 2 diabetes mellitus. Diabet Med. 2018 Dec;35(12):1663-1670. doi:10.1111/dme.13800. Epub 2018 Sep 19.; Sinclair A.J., Girling A.J., Bayer A. Cognitive dysfunction in older subjects with diabetes mellitus: impact on diabetes self‐management and use of care services. Diab. Res. Clin. Pract. 2000;50:203–212.; Lara-Rojas C.M., Pérez-Belmonte L.M., López- Carmona M.D., Guijarro-Merino R., Bernal-López M.R., Gómez-Huelgas R. National trends in diabetes mellitus hospitalization in Spain 1997– 2010: Analysis of over 5.4 millions of admissions. Eur. J. Intern. Med. 2019;60:83–89.; Mata-Cases M., Casajuana M., Franch-Nadal J., Casellas A., Castell C., Vinagre I., Mauricio D., Bolíbar B. Direct medical costs attributable to type 2 diabetes mellitus: A population-based study in Catalonia, Spain. Eur. J. Health Econ. 2016;17:1001–1010.; Котова О.В. Диабетическая автономная поли- невропатия. Фарматека. 2012;6:40-44. [Kotova O.V. Diabetic autonomous polyneuropathy. Pharmatheca [Farmateka]. 2012;6:40-44.] (In Russ.); Yıldırım Usta Y., Dikmen Y., Yorgun S., Berdo İ. Predictors of foot care behaviours in patients with diabetes in Turkey. Peer J. 2019 Feb 8;7:e6416. doi:10.7717/peerj.6416. eCollection2019.; Строков И.А. Диабетическая нейропатия. Эндокринология. Руководство для врачей. Под редакцией В.В. Потемкина. М.: МИА. 2013:385–401. [Strokov I.A. Diabeticheskaya neyropatiya. Endokrinologiya. Rukovodstvo dlya vrachey. Pod redaktsiey V.V. Potemkina. M.: MIA. 2013:385–401.] (In Russ.); Котова О.В. Диабетическая нейропатия. Применение нейротропных витаминов. Поликлиника. 2015;1(2):36-39. [Kotova O.V. Diabetic neuropathy. Application of neurotropic vitamins. Polyclinic [Poliklinika]. 2015;1(2):36- 39.] (In Russ.); Рябоконь И.В., Акарачкова Е.С., Вершинина С.В., Котова О.В. Диабетическая нейропатия: от патогенеза к терапии. Consilium Medicum. 2014;16(2):40-43. [Ryabokon I.V., Akarachkova E.S., Vershinina S.V., Kotova O.V. Diabetic neuropathy: from pathogenesis to therapy. Consilium Medicum [Consilium Medicum]. 2014;16(2):40-43.] (In Russ.); Feldman E.L., Nave K.A., Jensen T.S., Bennet D.L.H. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296–1313.; Котова О.В., Акарачкова Е.С. Диабетическая автономная полинейропатия. Журнал неврологии и психиатрии им. C.C. Корсакова. 2017;117(2):169-173. [Kotova O.V., Akarachkova E.S. Diabetic autonomous polyneuropathy. Journal of Neurology and Psychiatry named after A.V. Akarachkova, E.S. Diabetic autonomous polyneuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(2):169- 173.] (In Russ.); Котова О.В., Акарачкова Е.С. Кардиальная автономная полиневропатия: роль метаболической терапии. Consilium Medicum. 2016;18(4):28-30. [Kotova O.V., Akarachkova E.S. Cardial autonomous polyneuropathy: the role of metabolic therapy. Consilium Medicum [Consilium Medicum]. 2016;18(4):28-30.] (In Russ.); Rochette L., Ghibu S., Muresan A. et al. Alpha lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015;93(12):1021–1027.; Papanas N., Ziegler D. Efficacy of -lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721–2731.; Бреговский В.Б., Храмилин В.Н., Демидова И.Ю. и др. Диабетическая дистальная поли- нейропатия: обзор современных рекомендаций. Анналы клинической и экспериментальной неврологии. 2015:1(9):60–68. [Bregovskiy V.B., Khramilin V.N., Demidova I.Yu et al. Diabetic distal polyneuropathy: review of modern recommendations. Annals of clinical and experimental neurology [Annaly klinicheskoj i jeksperimental’noj nevrologii]. 2015:1(9):60–68.] (In Russ.); Строков И.А., Манухина Е.Б., Бахтина Л.Ю. и др. Состояние эндогенных протекторных систем у больных инсулинзависимым сахарным диабетом с полинейропатией: эффект антиоксидантной терапии. Бюлл. эксперимент. биол. и медиц. 2000;10(130):437–441. [Strokov I.A., Manukhina E.B., Bakhtina L.Yu et al. State of endogenous protector systems in patients with insulin-dependent diabetes mellitus with polyneuropathy: effect of antioxidant therapy. Bull. of experiment. biol. and medic. [Bjull. jeksperiment. biol. i medic.]. 2000;10(130):437–441.] (In Russ.); Borcea V., Nourooz-Zadeh J., Wolff S.P. et al. Alpha-lipoic acid decreases oxidative stress in patients with diabetes mellitus. Free Radic Biol Med. 1999;22:1495–1500.; Строков И.А., Фокина А.С., Ахмеджанова Л.Т., Баринов А.Н. Модернизация представлений о диабетической полиневропатии в период 2010–2018 гг. Трудный пациент. 2018:12(16):16-20. [Strokov I.A., Fokina A.S., Akhmedzhanova L.T., Barinov A.N. Modernization of the concept of diabetic polyneuropathy in the period 2010-2018. Difficult patient [Trudnyj pacient]. 2018:12(16):16-20.] (In Russ.); Дадашева М.Н., Подрезова Л.А., Каравашкина Е.А., Смирнова Л.А., Вишнякова Т.И. Роль анти- агрегантной терапии при цереброваскуляр- ной патологии. Клинический опыт применения дипиридамола. Трудный пациент. 2011;4:24-27. [Dadasheva M.N., Podrezova L.A., Karavashkina E.A., Smirnova L.A., Vishnyakova T.I. The role of antiplatelet therapy in cerebrovascular pathology. Clinical experience of application of dipyridamol. Difficult patient [Trudnyj pacient]. 2011;4:24-27.] (In Russ.); https://www.med-sovet.pro/jour/article/view/3033

الاتاحة: https://www.med-sovet.pro/jour/article/view/3033
https://doi.org/10.21518/2079-701X-2019-9-40-44

المؤلفون: N. N. Spirina, N. N. Spirin, A. N. Boyko

المصدر: Медицинский совет, Vol 0, Iss 18, Pp 68-73 (2015)

مصطلحات موضوعية: рассеянный склероз, эндотелий, эндотелиальная дисфункция, матоэнцефалический барьер, альфа-липоевая кислота, multiple sclerosis, endothelium, endothelial dysfunction, blood-brain barrier, alpha-lipoic acid, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/456; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/74ce05bcccfd48d3bd16c0d9ae6f2007

المؤلفون: O.Yu. Filippova

المصدر: HYPERTENSION; Том 13, № 4 (2020); 19-27
АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ; Том 13, № 4 (2020); 19-27
АРТЕРІАЛЬНА ГІПЕРТЕНЗІЯ; Том 13, № 4 (2020); 19-27

مصطلحات موضوعية: Coenzyme Q10, medicine.medical_specialty, business.industry, Alpha-Lipoic Acid, Lipid metabolism, альфа-липоевая кислота, коэнзим Q10, кардиоваскулярные заболевания, хронические диффузные заболевания печени, сахарный диабет, Липофарм, обзор, Carbohydrate, medicine.disease, alpha-lipoic acid, coenzyme Q10, cardiovascular diseases, chronic diffuse liver disease, diabetes mellitus, Lipofarm, review, chemistry.chemical_compound, Endocrinology, chemistry, Diabetes mellitus, Internal medicine, medicine, альфа-ліпоєва кислота, коензим Q10, кардіоваскулярні захворювання, хронічні дифузні захворювання печінки, цукровий діабет, Ліпофарм, огляд, In patient, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcecb942de0be92d04fe6b44baccbe7b
https://doi.org/10.22141/2224-1485.13.4.2020.211956

المؤلفون: N. Pizova V., Н. Пизова В.

المصدر: Meditsinskiy sovet = Medical Council; № 9 (2018); 104-111 ; Медицинский Совет; № 9 (2018); 104-111 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-9

مصطلحات موضوعية: diabetes mellitus, diabetic neuropathies, alpha-lipoic acid, сахарный диабет, диабетические нейропатии, альфа-липоевая кислота

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/2483/2460; Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care, 2004 May, 27(5): 1047-53.; Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр больных сахарным диабетом в РФ: статус 2014 г. и перспективы развития. Сахарный диабет, 2015, 18(3): 5-22.; Martyn C, Hughes R. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry, 1997, 62(4): 310-18.; Dyck P, Thomas P. Diabetic Neuropathy. 2nd ed. Philadelphia: W.B. Saunders, Co., 1999.; Pirart J. Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care, 1978, 1(3): 252-63.; McNeely M, Boyko E, Ahroni J et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care, 1995, 18(2): 216-9.; Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology, 1993, 43(4): 817-24.; Feldman EL, Russell JW, Sullivan KA, Golovoy D. New insights into the pathogenesis of diabetic neuropathy. Curr Opin Neurol, 1999, 12(5): 553-63.; Яхно Н.Н., Кукушкин М.Л., Давыдов О.С. и др. Результаты Российского эпидемиологического исследования распространенности нейропатической боли, ее причин и характеристик в популяции амбулаторных больных, обратившихся к врачу-неврологу (EPIC Study). Боль, 2008, 3: 24–32.; Sorensen L, Molyneaux L, Yue DK. Insensate versus painful diabetic neuropathy: the effects of height, gender, ethnicity and glycaemic control. Diabet Res Clin Pract, 2002, 57: 45–51.; Ziegler D, Gries FA, Spuler M, Lessmann F. The epidemiology of diabetic neuropathy: DiaCAN Multicenter Study Group. Diabet Med, 1993, 10: 82–6.; Daousi C, MacFarlane IA, Woodward A et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med, 2004, 21: 976-982.; Malik RA. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors? Ann Med, 2000, 32(1): 1-5.; Benbow SJ, MacFarlane IA. Painful diabetic neuropathy. Baillieres Best Pract Res Clin Endocrinol Metab, 1999, 13(2): 295-308.; Potter P, Maryniak O, Yaworski R, Jones I. Incidence of peripheral neuropathy in the contralateral limb of persons with unilateral amputation due to diabetes. J Rehabil Res Dev, 1998, 35(3): 335-9.; Russell JW, Zilliox LA. Diabetic neuropathies. Continuum (Minneap Minn), 2014, 20(5 Peripheral Nervous System Disorders): 1226-40.; Bansal V, Kalita J, Misra UK. Diabetic neuropathy. Postgrad Med J, 2006, 82: 95-100.; Dyck P, Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol, 1996, 55(12): 1181-93.; Thomas P, Tomlinson D. Diabetic and hypoglycemic neuropathy. Dyck P, Thomas P, eds. Peripheral Neuropathy. 3rd ed. Philadelphia: W.B. Saunders Company, 1993: 1219-50.; Tesfaye S, Stevens L, Stephenson J et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM complications study. Diabetologia, 1996, 39(11): 1377-1384.; Ropper AH, Samuels MA (eds). Adams and Victor’s Principles of Neurology, ed 9. New York, McGraw-Hill, 2009, chapter 46.; Poncelet A. An algorithm for the evaluation of peripheral neuropathy. American Family Physician, 1998, 57(4): 755-64.; American Diabetes Association, National Heart, Lung and Blood Institute, Juvenile Diabetes Foundation International, National Institute of Diabetes and Kidney Disease, American Heart Association. Diabetes mellitus: a major risk factor for cardiovascular disease. Circulation, 1999, 100: 1132-1133.; Дедов И.И., Александров А.А. Факторы риска ишемической болезни сердца у больных сахарным диабетом типа 2: роль гиперсимпатикотонии и возможности ее коррекции. Качество жизни. Медицина. 2003: 16-21.; Всемирное руководство по сахарному диабету 2 типа. Укр. мед. вісник, 2006, 3: 5-10./ Worldwide guidelines for type 2 diabetes mellitus. Ukr. med. visnyk, 2006, 3: 5-10; Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham Study. JAMA, 1979, 241: 2035-2038.; Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had a myocardial infarction: cross sectional and cohort studies. BMJ, 2002, 324: 939-942.; Howard BV, Rodrigues BL, Bennett PH et al. Diabetes and Cardiovascular Disease: Writing Group I: epidemiology. Circulation, 2002, 105: 132-137.; Дедов И.И. Сахарный диабет в Российской Федерации: проблемы и пути решения. Сахарный диабет, 1998, 1: 7-18.; Токмакова А.Ю., Староверова Д.Н. Современные методы ранней диагностики диабетической макроангиопатии. Пробл. эндокринол., 2005, 51(3): 39-40.; Чазова Т.Е., Катхурия Ю.Б. Сахарный диабет и сердечно-сосудистые заболевания: факторы риска, клинические особенности, диагностика. Мед. помощь, 2001, 5: 28-32.; Арутюнов Г.Л. Сахарный диабет и атеросклероз: какова оптимальная стратегия сдерживания атеросклеротического процесса? Сердце, 2004, 3(1): 36-38.; Давыдов А.Л., Баранова Л.Ю. Особенности гисто- и ультраструктурной организации миокарда и стенки сосудов у больных сахарным диабетом типа 2. Пробл. эндокринол., 2005, 51(3): 38.; Дедов И.И., Шестакова М.В. Сахарный диабет. М., 2003: 220-222.; Watkins PJ, Thomas PK. Diabetes mellitus and the nervous system. J Neurol Neurosurg Psychiatr, 1998, 65: 620-633.; Маньковский Б.Н. Сахарный диабет и цереброваскулярные заболевания. Новости медицины и фармации, 2007, 216: 21-23.; Балаболкин М.И. Диабетология. М.: Медицина, 2000, 672 с.; Ефимов А., Зуева Н., Скробонская Н. Диабетические ангиопатии: этиология и патогенез. Ліки України. 2004, листопад, 36-38.; Miles WR, Root HF. Arch Int Med, 1922, 30: 767770.; Kodl CT, Seaquist ER. Cognitive dysfunction and diabetes mellitus. Endocr Rev, 2008, 29(4): 494-511.; Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, Ritterband LM, Magee JC, Cox DJ et al. Cognitive function isdisrupted by both hypo- and hyperglycemia in schoolaged children with type 1 diabetes: a field study. Diabetes Сare, 2009, 32(6): 1101–6.; Xiao-jun Cai, Hui-qin Xu, Yi Lu. C-peptide and Diabetic Encephalopathy. Chin Med Sci J, 2011, 26(2): 119–25.; Чуйко М.Р., Бодыхов М.К., Скворцова В.И. Характеристика и особенности течения энцефалопатии при инсулинзависимом сахарном диабете. Журнал неврологии и психиатрии им. С.С. Корсакова, 2010, 5: 4–8.; Patino-Fernandez AM, Delamater AM, Applegate EB et al. Neurocognitive functioning in preschool-age children with type 1 diabetes mellitus. Pediatric Diabetes, 2010, 11(6): 424–30.; Biessels GJ, Luchsinger JA. Pathobiology of diabetic encephalopathy in animal models. Diabetes and the brain contemporary diabetes. N.Y.: Springer, LLC, 2010: 409–31.; Brands AMA, Biessels GJ, De Haan EHF, Kappelle LJ, Kessels RPC. The effects of type 1 diabetes on cognitive performance: a metaanalysis. Diabetes Care, 2005, 28: 726–35.; Perantie DC, Koller JM, Weaver PM, Lugar HM, Black KJ, White NH et al. Prospectively determined impact of type 1 diabetes on brain volume during development. Diabetes, 2011, 60 (11): 3006–14.; Brands AM, Biessels GJ, Kappelle LJ, de Haan EH, de Valk HW, Algra A et al. Cognitive functioning and brain MRI in patients with type 1 and type 2 diabetes mellitus: a comparative study. Dement Geriatr Cogn Disord, 2007, 23 (5): 343–50.; Ho MS, Weller NJ, Ives FJ et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr, 2008, 153: 385–90.; Strachan MWJ, Reynolds RM, Frier BM et al. The relationship between type 2 diabetes and dementia. Br Med Bui, 2008, 88: 131-146.; Fontbonne A, Berr С, Ducimetiere P, Alperovitch A. Changes in cognitive abilities over a 4-yearperiod are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. Diabet Care 2001, 24: 366-370.; Messier C. Impact of impaired glucose tolerance and type 2 diabetes on cognitive aging. Neurobiol Aging, 2005, 26(Suppl. 1): 26-30.; Mijnhout GS, Scheltens P, Diamant M, et al. Diabetic encephalopathy: A concept in need of a definition. Diabetologia, 2006, 49: 14471448.; Biessels GJ, Staekenborg S, Brunner E et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol, 2006, 5(1): 64-74.; Ott A, Stolk RP, Hofman A, et al. Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia, 1996, 39: 1392-1397.; Yoshitake Т, Kiyohara Y, Kato I, et al. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology, 1995, 45: 1161-1168.; Строков И.А., Моргоева Ф.Э., Строков К.И. и др. Терапевтическая коррекция диабетической полиневропатии и энцефалопатии Актовегином. РМЖ, 2006, 9: 698–703.; Чугунов П.А., Семенова И.В. Сахарный диабет и когнитивные нарушения. Сахарный диабет, 2008, 1(38): 61–68.; Reaven G, Thompson L, Nahum D, Haskins E. Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care, 1990, 13: 16–21.; Nielson KA, Nolan JH, Berchtold NC, Sandman CA, Mulnard RA, Cotman CW. Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer’s disease? J Am Geriatr Soc, 1996, 44: 897–904.; Sima AA, Kamiya H, Li ZG. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. Eur J Pharmacol, 2004, 490: 187–197.; Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA, 2002, 287: 2570–2581.; Ефимов А.С. Диабетические ангиопатии. М.: Медицина, 1989. 288 с./ Efimov AS. Diabetic angiopathies. M.: Medicine. 1989. 288 p.; Wredling R, Levander S, Adamson U. Permanent neuropsychological impairment after recurrent episodes of severe hypoglicaemia in men. Diabetologia, 1990, 33: 152–157.; American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care, 2011, 34(suppl 1): S11-S61.; Hartemann A, Attal N, Bouhassira D, Dumont I, Gin H, Jeanne S, Said G, Richard JL, Working Group on the Diabetic Foot from the Frenchspeaking Society of Diabetology: Painful diabetic neuropathy: diagnosis and management. Diabetes Metab, 2011, 37: 377-388.; Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med, 1993, 1993(329): 977-86.; Group UP. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 1998: 703-13.; International Diabetes Federation. Clinical Practice Recommendation on the Diabetic Foot: A guide for health care professionals : International Diabetes Federation, 2017.; Pfeifer MA, Schumer MP. Clinical trials of diabetic neuropathy: past, present, and future. Diabetes, 1995 Dec, 44(12): 1355-61.; Oates PJ, Klioze SS & the Zopolrestat Diabetic Neuropathy Study Group. Chronic treatment with aldose reductase inhibitor zopolrestat suppressed sorbitol, but not fructose, in sural nerves of patients with diabetic neuropathy. Diabetologia, 2007, 50(Suppl.1): S62(0136).; Котов С.В., Калинин А.П., Рудакова И.Г. Диабетическая нейропатия. М.: ООО «Издательство «Медицинское информационное агенство», 2011, 440 с.; Tanenberg R, Schummer M, Green D, Pfeifer M. The Diabetic Foot, 6th ed. Mosby, 2001: 33-64.; Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies. Diabetologia, 2000, 43(8): 957-73.; Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. The Lancet, 1998 Dec 26, 352(9145): 1978-81.; Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New England Journal of Medicine, 1988, 318(20): 1315-21.; Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia, 1992, 35(10): 946-50.; Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain research, 1994, 634(1): 7-12.; Seckel BR. Enhancement of peripheral nerve regeneration. Muscle & nerve, 1990, 13(9): 785-800.; Бустаманте Д., Лодж Д., Маркоччи Л., Тришлер Г. Метаболизм а-липоевой кислоты в печени при различных формах патологии. Междун. мед. журн., 2001, 2: 133–142.; Rochette L, Ghibu S, Richard C, Zeller M, et al. Direct and indirect antioxidant properties of α-lipoic acid and therapeutic potential. Mol Nutr Food Res, 2013, 57(1): 114-125.A; Stevens MJ, Obrosova I, Cao X, Van Huysen C, Greene DA. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes, 2000, 49(6): 1006–1015.; van Dam PS, van Asbeck BS, Van Oirschot JF, Biessels GJ, Hamers FP, Marx JJ. Glutathione and alpha-lipoate in diabetic rats: nerve function, blood flow and oxidative state. Eur J Clin Invest, 2001, 31(5): 417–424.; Ford I, Cotter MA, Cameron NE, Greaves M. The effects of treatment with alpha-lipoic acid or evening primrose oil on vascular hemostatic and lipid risk factors, blood flow, and peripheral nerve conduction in the streptozotocin-diabetic rat. Metabolism, 2001, 50(8): 868–875.; Sun L, Chen Y, Wang X et al. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochem Pharmacol, 2012, 84(7): 961-973.; Heitzer T, Finckh B, Albers S. Benefficial effects of alpha-lipoic acid and ascorbic acid on endothelium-dependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parameters of oxidative stress. Free Radic Biol Med, 2001, 31: 53-61.; Reljanovic M, Reichel G, Rett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res, 1999, 31(3): 171–9.; Ziegler D, Hanefeld M, Ruhnau RJ et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alphalipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care, 1999, 22(8): 1296–301.; Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant α-lipoic acid. A 3-week multicentre randomized controlled trial (ALA-DIN Study). Diabetologia, 1995, 38: 1425–33.; Ametov A, Barinov A, O’brien P, Dyck PJ, Herman R, Litchy WJ et al, the SYDNEY Trial Study Group. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The SYDNEY Trial. Diabetes Care, 2003, 26: 770-776.; Monograph a-lipoic acid. Alternative Med Rev, 1998, 3/4: 308–10.; Kagan VE, Shvedova A, Serbinova E et al. Biochem. Pharmacol, 1992, 44: 1637–49.; Bridges RJ, Koh JY, Hatakski CG, Cotman CW. Increased excitotoxic vulnerability of cortical cultures with reduced levels of glutathione. Eur J Pharmacol, 1991, 192: 199–200.; Busse E, Zimmer G, Schopohl B, Kornhuber B. Influence of alpha-lipoic acid on intracellular glutathione in vitro and in vivo. Arzneimittelforsch, 1992, 42: 829–31.; Han D, Trischler HJ, Packer L. Alpha-lipoic acid increases intracellular glutathione in a human T-lymphocyte jurkat cell line. Biochem Biophys Res, 1995, 207: 258–64.; Бурчинский С.Г. Стратегия антиоксидантной нейропротекции: новые возможности. Здоровье Украины, 2008, 19.; Cao X, Phillis JW. The free radical scavenger, alpha-lipoic acid, protects against cerebral ischemia-reperfusion injury in gerbils. Free Radical Research, 1995, 23(4): 365-370.; Стаховская Л.В., Шеховцова К.В., Кербиков О.Б. Антиоксидантная терапия в раннем восстановительном периоде ишемического инсульта (результаты исследования «ПОБЕДА»). Consilium Medicum. Приложение Неврология, 2009, 1: 27-31.; Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care, 2010, 33(10): 2285-2293.; Tesfaye S, Vileikyte L, Rayman G et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev, 2011, 27: 629-638.; Bril V, England J, Franklin GM et al. Evidencebased guideline: treatment of painful diabetic neuropathy. Report of American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the AmericanAcademy of Physical Medicine and Rehabilitation. Neurology, 2011, 76: 1758-1765.; Левин О.С. Диабетическая полиневропатия: современные подходы к диагностике и патогенетической терапии. Клиницист, 2013, 2: 54-62.; https://www.med-sovet.pro/jour/article/view/2483

الاتاحة: https://www.med-sovet.pro/jour/article/view/2483
https://doi.org/10.21518/2079-701X-2018-9-104-111

المؤلفون: Zhuravlyova, L. V., Lopina, N. A.

المصدر: UMJ Heart & Vessels; No. 1 (2018); 102-110 ; Сердце и сосуды; № 1 (2018); 102-110 ; Серце і судини; № 1 (2018); 102-110 ; 2521-6910 ; 1727-5717

مصطلحات موضوعية: альфа-ліпоєва кислота, біохімічна дія, серцево-судинні захворювання, цукровий діабет, ендотеліальна дисфункція, оксидативний стрес, alpha-lipoic acid, biochemical action, cardiovascular diseases, diabetes mellitus, endothelial dysfunction, oxidative stress, альфа-липоевая кислота, биохимическое действие, сердечно-сосудистые заболевания, сахарный диабет, эндотелиальная дисфункция, оксидативный стресс

وصف الملف: application/pdf

Relation: https://heartandvessels.co.ua/article/view/HV201811021/122134; https://heartandvessels.co.ua/article/view/HV201811021

الاتاحة: https://heartandvessels.co.ua/article/view/HV201811021

المؤلفون: I. A. Strokov, A. S. Fokina, K. I. Strokov, О. О. Drokonova

المصدر: Медицинский совет, Vol 0, Iss 5, Pp 38-43 (2014)

مصطلحات موضوعية: диабетическая полинейропатия, дисталь-ная симметричная сенсорно-моторная полинейропатия, патогенетическая терапия дпн, альфа-липоевая кислота, diabetic neuropathy, sensorimotor distal symmetric polyneuropathy, pathogenetic therapy of dpn, alpha-lipoic acid, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/566; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/017c18bed9cd4a56bd537a2ff9069ee1

المؤلفون: L. Y. Morgunov

المصدر: Медицинский совет, Vol 0, Iss 17, Pp 90-95 (2014)

مصطلحات موضوعية: диабетическая нейропатия, альфа-липоевая кислота, diabetic neuropathy, alpha-lipoic acid, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/781; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/a6cdf2924cb1422696e19192f077174f

المؤلفون: L. V. Nedosugova

المصدر: Медицинский совет, Vol 0, Iss 12, Pp 43-49 (2013)

مصطلحات موضوعية: диабетическая периферическая полинейро-патия, дегенеративная аксонопатия, диабетическая стопа, патогенетическая терапия, альфа-липоевая кислота, diabetic peripheral neuropathy, degenerative axonopathy, diabetic foot, pathogenetic therapy, alpha-lipoic acid, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/1162; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/11b8ecff16914ef6bc86c223c2bee058

المؤلفون: Zaremba, E. H., Smalyukh, O. V.

المصدر: Клінічна та експериментальна патологія; Том 16 № 2 (2017) ; Клиническая и экспериментальная патология; Том 16 № 2 (2017) ; Clinical & experimental pathology; Vol. 16 No. 2 (2017) ; 1727-4338

مصطلحات موضوعية: statins, alpha-lipoic acid, lipids, C-reactive protein, статины, альфа-липоевая кислота, липидный спектр, С-реактивный белок, статини, альфа-ліпоєва кислота, ліпідний спектр, С-реактивний протеїн

وصف الملف: application/pdf

Relation: http://cep.bsmu.edu.ua/article/view/1727-4338.XVI.2.60.2017.5/108551; http://cep.bsmu.edu.ua/article/view/1727-4338.XVI.2.60.2017.5

الاتاحة: http://cep.bsmu.edu.ua/article/view/1727-4338.XVI.2.60.2017.5
https://doi.org/10.24061/1727-4338.XVI.2.60.2017.5

المؤلفون: Юзвенко, Т. Ю., Крушинська, З. Г., Тарасенко, С. О.

المصدر: Clinical Endocrinology and Endocrine Surgery; No. 4(60) (2017); 23-29 ; Clinical Endocrinology and Endocrine Surgery; № 4(60) (2017); 23-29 ; 2519-2582 ; 1818-1384

مصطلحات موضوعية: alpha-lipoic acid, tioctic acid, diabetes mellitus complications, diabetic neuropathy, альфа-липоевая кислота, тиоктовая кислота, осложнения сахарного диабета, диабетическая нейропатия, альфа-ліпоєва кислота, тіоктова кислота, ускладнення цукрового діабету, діабетична невропатія

وصف الملف: application/pdf

Relation: http://jcees.endocenter.kiev.ua/article/view/118735/113685; http://jcees.endocenter.kiev.ua/article/view/118735

الاتاحة: http://jcees.endocenter.kiev.ua/article/view/118735
https://doi.org/10.24026/1818-1384.4(60).2017.118735